Compounds for degrading TAU protein aggregates and uses thereof
By developing bispecific binding compounds that can specifically bind tau protein aggregates and recruit ubiquitin E3 conjugase, the problem of the inability of the prior art to effectively treat tau protein diseases is solved, and the removal of pathological tau proteins and normalization is achieved. The protection of tau protein significantly slowed down the progress of neurodegenerative diseases.
Patent Information
- Application Number
- CN202080078757.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-11-13
- Filing Date
- 2020-11-13
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-11-13
AI Technical Summary
Existing treatments cannot effectively prevent, prevent or reverse the progress of tau disease, and it is difficult to distinguish between pathological and normal tau proteins to avoid disruption of cellular function.
A bispecific binding compound was developed that specifically binds aggregates of tau protein and recruits ubiquitin E3 conjugase to label aggregates, thereby promoting their degradation and distinguishing between pathological and normal tau proteins.
This compound has clinically promoted the scavenging potential of pathogenic tau protein, reduced the impact on normal tau protein, and is effectively used to treat neurodegenerative diseases associated with tau aggregates.
Smart Images

Figure CN114728071B_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to compounds suitable for degrading TAU protein aggregates and uses thereof. Background Art
[0002] Neurodegenerative diseases are estimated to affect 50 million Americans each year, resulting in an inestimable personal burden and an economic cost of hundreds of billions of dollars in medical expenses and lost productivity each year. Tauopathies are a class of neurodegenerative diseases associated with pathological aggregation of Tau protein (microtubule-associated protein tau, MAPT) in the human brain, and include Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), Parkinson's disease (PD), Pick's disease (PiD), and progressive supranuclear palsy (PSP). In tauopathies, Tau aggregates spread through the brain in a prion-like manner, such as seen in AD brains (H. Braak et al., Neurobiol Aging (1995), 16(3):271-78; H. Braak et al., Acta Neuropathol (2006) 112(4):389-404), where Tau pathology manifests itself in a constant spatiotemporal pattern. Tau propagation seeds, primarily composed of short fibrils, have been found to be significantly enriched in the synaptic fraction of brain regions without extensive cellular Tau pathology, indicating that Tau seeds can spread through the human brain along synaptically connected neuronal networks.
[0003] Although many therapeutic approaches aimed at removing aggregated Tau species have been studied or are currently being studied, there is currently no effective treatment to arrest, prevent or reverse the progression of such neurodegenerative diseases. Therefore, there is a need for novel agents that can slow the progression of such neurodegenerative diseases and / or prevent their occurrence. In addition, there is a need for agents that distinguish between pathological forms of tau and tau in its normal functional configuration so that its normal intracellular function is not disrupted. Summary of the invention
[0004] The present invention relates to novel bispecific binding compounds that bind to Tau aggregates and recruit ubiquitin E3 conjugase to mark the aggregates for proteomic degradation and clearance. These compounds specifically bind to Tau aggregates and distinguish Tau aggregates from monomeric (normal) Tau. These results indicate the suitability of the compounds for clinical use, which have the potential to promote the clearance of pathogenic Tau in the clinic, and have minimal impact on normal / physiological Tau species in the brains of human tauopathy patients.
[0005] The present invention provides compositions and methods for treating a group of disorders and abnormalities associated with Tau aggregates. The methods of the present invention include administering to an individual a bispecific binder or pharmaceutical composition described herein, which comprises a therapeutically effective amount of a compound of the present invention that is effective in treating, alleviating or preventing a disorder or abnormality associated with Tau aggregates. In certain embodiments, a therapeutically effective amount of a compound described herein is effective in preventing, preventing or reversing the progression of a neurodegenerative disease.
[0006] In some embodiments, pharmaceutical compositions of compounds for treating Tau-related neurodegenerative diseases are provided. The provided compositions include an effective amount of a compound as described herein and a pharmaceutically acceptable excipient.
[0007] One aspect of the present invention is a compound of any one of formula (I)-(VI):
[0008]
[0009] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein L1, L2, L3, X, Y, J, Q, K, T, U, V, Z, Y1, R', R", R'", R 2 '、R 3 ', n, m, k and m6 are as defined herein.
[0010] Another aspect of the present invention is a composition comprising a compound of the present invention and a pharmaceutically acceptable excipient.
[0011] Another aspect of the present invention is a method for adjunctive treatment of tauopathy in an individual, the method comprising administering an effective amount of a compound or composition of the present invention, wherein the compound or composition treats or adjunctively treats the individual.
[0012] Another aspect of the present invention is the use of the compounds of the present invention for treating tauopathy or tau-related diseases or disorders.
[0013] Another aspect of the present invention is the use of a compound of the present invention for the manufacture of a medicament for treating tauopathy or a tau-related disease or disorder.
[0014] Another aspect of the present invention is the use of the compounds of the present invention for diagnosing tauopathy or tau-related diseases or disorders.
[0015] Another aspect of the invention is a kit comprising a compound of the invention or a composition of the invention and printed instructions for its use.
[0016] Another aspect of the present invention is a method for synthesizing the compounds of the present invention.
[0017] The foregoing summary is illustrative only and is not intended to be limiting in any way. In addition to the illustrative embodiments and features described herein, other aspects, embodiments, objects and features of the invention will become fully apparent from the drawings and detailed description and the scope of the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 Degradation of Tau aggregates measured by APNmAb005 ELISA analysis is shown. After 1 μM compound 162842 treatment, the optical density (OD) 450 value decreased by 20% compared to vehicle, reflecting a reduction in Tau aggregates. DETAILED DESCRIPTION
[0019] CROSS REFERENCE TO RELATED APPLICATIONS
[0020] This application claims priority to U.S. Provisional Application No. 62 / 935,017, filed on November 13, 2019, the contents of which are incorporated herein by reference in their entirety.
[0021] The present invention provides compounds that specifically bind to aggregated forms of Tau protein and also bind to ubiquitin E3 ligases. E3 ligases are intracellular enzymes that transfer activated ubiquitin to specific sites on targeted proteins.
[0022] Ubiquitin is a highly conserved small protein (8 kDa, 76 amino acids) that is ubiquitously expressed in cells. After expression, ubiquitin is activated by ubiquitin-activating enzymes ("E1") and subsequently transferred to ubiquitin-conjugating enzymes ("E2"). E3 conjugating enzymes transfer ubiquitin from the E2 enzyme to the target substrate. It is estimated that there are more than 600 different E3 conjugating enzymes that recognize a variety of different protein substrates. Once ubiquitinated, the substrate is transferred to the proteasome, which degrades the protein into oligopeptides, which ultimately degrade these oligopeptides into single amino acids. The ubiquitin-proteasome system serves to regulate the concentration of some proteins and to degrade and recycle damaged or misfolded proteins.
[0023] The present invention provides compositions and methods for treating a group of disorders and abnormalities associated with Tau aggregates. The methods of the present invention include administering to an individual a compound or pharmaceutical composition described herein, which comprises a therapeutically effective amount of a compound of the present invention that is effective in treating, alleviating or preventing a disorder or abnormality associated with Tau aggregates. In certain embodiments, a therapeutically effective amount of a compound described herein is effective in preventing, preventing or reversing the progression of a neurodegenerative disease.
[0024] One aspect of the present invention is a compound of any one of formula (I)-(VI):
[0025]
[0026]
[0027] Wherein in Formula I, R 3 ' is H or C 1-6 Alkyl; Y1 is CH2 or L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L3 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; V is N, wherein Z and U are not heteroatoms at the same time; K is CH or N; Q is CH or N; wherein K and Q are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkylamino, C 3-6 Cycloalkyl and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; J is CR 6 or N; X is CR 6 or N; Y is CR 6 or N; wherein at least one of J, X and Y is N, but J and Y are not N at the same time, and X and Y are not N at the same time; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl and / or halo substituents;
[0028] In Formula II, R 2' is independently selected at each occurrence from the group consisting of: H, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Y1 is CH2 or L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; V is N, wherein Z and U are not heteroatoms at the same time; K is CH or N; Q is CH or N; wherein K and Q are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; J is CR 6 or N; X is CR 6 or N; Y is CR 6 or N; wherein at least one of J, X and Y is N, but J and Y are not N at the same time, and X and Y are not N at the same time; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl and / or halo substituents;
[0029] In Formula III, L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50a hydrocarbon chain; Z is C or N; U is O, S or CH; V is N, wherein Z and U are not heteroatoms at the same time; K is CH or N; Q is CH or N; wherein K and Q are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; J is CR 6 or N; X is CR 6 or N; Y is CR 6 or N; wherein at least one of J, X and Y is N, but J and Y are not N at the same time, and X and Y are not N at the same time; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl and / or halo substituents;
[0030] In Formula IV, R 3 ' is H or C 1-6 Alkyl; Y1 is CH2 or L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L3 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; V is N or NH; T is CH or N; wherein at most two of U, Z, V and T contain heteroatoms; K is CH or N; Q is CH or N; wherein K and Q are not N at the same time; R'' is independently selected from the group consisting of H, OH, NH2, C1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; J is CR 6 or N; X is CR 6 or N; Y is CR 6 or N; wherein at least one of J, X and Y is N, but J and Y are not N at the same time, and X and Y are not N at the same time; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl and / or halo substituents;
[0031] In Formula V, R 2 ' is independently selected at each occurrence from the group consisting of: H, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Y1 is CH2 or L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; V is N or NH; T is CH or N; wherein at most two of U, Z, V and T contain heteroatoms; K is CH or N; Q is CH or N; wherein K and Q are not N at the same time; R'' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; J is CR 6 or N; X is CR 6 or N; Y is CR 6 or N; wherein at least one of J, X and Y is N, but J and Y are not N at the same time, and X and Y are not N at the same time; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl and / or halo substituents;
[0032] In Formula VI, L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; V is N; T is CH or N; wherein at most two of U, Z, V and T contain heteroatoms; K is CH or N; Q is CH or N; wherein K and Q are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; J is CR 6 or N; X is CR 6 or N; Y is CR 6 or N; wherein at least one of J, X and Y is N, but J and Y are not N at the same time, and X and Y are not N at the same time; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl groups and / or halogen groups are substituted.
[0033] In certain embodiments, the compound has the structure of Formula I.
[0034] In certain embodiments, the compound has the structure of Formula II.
[0035] In certain embodiments, the compound has the structure of Formula III.
[0036] In certain embodiments, the compound has the structure of Formula IV.
[0037] In certain embodiments, the compound has the structure of Formula V.
[0038] In certain embodiments, the compound has the structure of Formula VI.
[0039] In certain embodiments, the moieties in formula (I), (II) and (III) for
[0040] In certain embodiments, the moieties in formulas (IV), (V) and (VI) for
[0041] In certain embodiments, the moiety in formula (I)-(VI) for
[0042] In certain embodiments, the moieties in formula (I) and (IV) for
[0043] In certain embodiments, the moieties in formula (II) and (V) for
[0044] In one embodiment of the present invention, L1 is a bond.
[0045] In one embodiment of the present invention, L1 is -NH-, -O- or -S-.
[0046] In one embodiment of the present invention, L3 is a bond.
[0047] In one embodiment of the present invention, L3 is -NH-, -O- or -S-.
[0048] In one embodiment of the present invention, L2 is a substituted or unsubstituted C 1-30 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group.
[0049] In certain embodiments, L2 is unsubstituted C 1-30 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group.
[0050] In certain embodiments, L2 is substituted or unsubstituted C 1-24 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group.
[0051] In certain embodiments, L2 is unsubstituted C 1-24 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group.
[0052] In certain embodiments, L2 is substituted or unsubstituted C 1-20 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group.
[0053] In certain embodiments, L2 is unsubstituted C 1-20 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group.
[0054] In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced by -O-.
[0055] In certain embodiments, the chain length of L2 comprises up to 50 consecutive covalently bonded atoms, excluding hydrogen atoms and substituents.
[0056] In certain embodiments, L2 comprises up to, for example, 46, 45, 40, 35, 32, 30, 25, 23, 20, 15, 14, 12, 11, 10, 9, 8, 7, 6, 5, 3 consecutive covalently bonded atoms in length, excluding hydrogen atoms and substituents.
[0057] In certain embodiments, any of the atoms in L2 may be substituted. In certain embodiments, none of the atoms in the linking group L2 are substituted. In certain embodiments, none of the carbon atoms in the linking group are substituted.
[0058] In certain embodiments, L2 is a linking group containing an asymmetric carbon / stereocenter, i.e., an sp3-mixed carbon atom with 4 different groups attached thereto. In certain embodiments, compounds comprising such L2 groups are enantiomerically enriched or substantially enantiomerically enriched. In certain embodiments, compounds comprising such L2 groups are enantiomerically pure. In certain embodiments, compounds comprising such L2 groups are racemic.
[0059] In certain embodiments, L2 comprises a substituted or unsubstituted carbocyclylene, a substituted or unsubstituted heterocyclylene, a substituted or unsubstituted arylene, a substituted or unsubstituted heteroarylene, or a substituted or unsubstituted heteroalkylene, or a combination thereof. In certain embodiments, L2 is a substituted or unsubstituted carbocyclylene, a substituted or unsubstituted heterocyclylene, a substituted or unsubstituted arylene, a substituted or unsubstituted heteroarylene, or a substituted or unsubstituted heteroalkylene. In certain embodiments, L2 is a linker selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, substituted and unsubstituted heterocyclylene, substituted and unsubstituted carbocyclylene, substituted and unsubstituted arylene, substituted and unsubstituted heteroarylene, and a combination thereof.
[0060] Reference to L2 as a combination of at least two instances of a divalent moiety described herein refers to a linking group consisting of at least one instance of the first divalent moiety and at least one instance of the second divalent moiety, wherein the first and second divalent moieties are the same or different and within the scope of divalent moieties described herein, and the instances of the first and second divalent moieties are continuously covalently linked to each other. For example, when L2 is a combination of an alkylene and heteroalkylene linking group, -alkylene-heteroalkylene-, -alkylene-(heteroalkylene)2-, and -heteroalkylene-alkylene-heteroalkylene- are all within the scope of L2, wherein each instance of the alkylene in any of the linking groups can be the same or different, and each instance of the heteroalkylene in any of the linking groups can be the same or different.
[0061] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted alkylene group, such as a substituted or unsubstituted C 1-6 Alkylene, substituted or unsubstituted C 1-2 Alkylene, substituted or unsubstituted C 1-3 Alkylene, substituted or unsubstituted C 3-4 Alkylene, substituted or unsubstituted C 4-5 Alkylene, substituted or unsubstituted C 5-6 Alkylene, substituted or unsubstituted C 3-6 Alkylene or substituted or unsubstituted C 4-6 Alkylene. Exemplary alkylene groups include unsubstituted alkylene groups such as methylene (—CH2—), ethylene (—(CH2)2—), n-propylene (—(CH2)3—), n-butylene (—(CH2)4—), n-pentylene (—(CH2)5—), and n-hexylene (—(CH2)6—).
[0062] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted alkenylene group, such as a substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 1-3 Alkenyl, substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 Alkenyl.
[0063] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted alkynylene group, such as a substituted or unsubstituted C 2-6 Alkyne, substituted or unsubstituted C 2-3 Alkyne, substituted or unsubstituted C 3-4 Alkyne, substituted or unsubstituted C 4-5 Alkyne or substituted or unsubstituted C 5-6 Alkynyl.
[0064] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted heteroalkylene group, such as a substituted or unsubstituted heteroC 1-6 Alkylene, substituted or unsubstituted hetero C 1-2 Alkylene, substituted or unsubstituted hetero C 2-3 Alkylene, substituted or unsubstituted hetero C 3-4 Alkylene, substituted or unsubstituted hetero C 4-5 Alkylene or substituted or unsubstituted hetero C 5-6 Exemplary heteroalkylene groups include unsubstituted heteroalkylene groups such as -(CH2)2-O(CH2)2-, -OCH2-, -CH2O-, -O(CH2)2-, -(CH2)2O-, -O(CH2)3-, -(CH2)3O-, -O(CH2)4-, -(CH2)4O-, -O(CH2)5-, -(CH2)5O-, -O(CH2)6-, and -O(CH2)6O-, and amide groups (e.g., -NH-C(=O)- and -C(=O)NH-).
[0065] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted heteroalkenyl group, such as a substituted or unsubstituted heteroC 2-6 Alkenyl, substituted or unsubstituted hetero 1-3 Alkenyl, substituted or unsubstituted hetero 3-4 Alkenyl, substituted or unsubstituted hetero 4-5 Alkenyl or substituted or unsubstituted hetero C 5-6 Alkenyl.
[0066] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted heteroalkynyl group, such as a substituted or unsubstituted heteroC 2-6 Alkyne, substituted or unsubstituted hetero 2-3 Alkyne, substituted or unsubstituted hetero 3-4 Alkyne, substituted or unsubstituted hetero 4-5 Alkyne or substituted or unsubstituted hetero C 5-6 Alkynyl.
[0067] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted carbocyclyl group, such as a substituted or unsubstituted C 3-6 A carbonyl group, a substituted or unsubstituted C 3-4 A carbonyl group, a substituted or unsubstituted C 4-5 A carbonyl group or a substituted or unsubstituted C 5-6 Extended carbon ring group.
[0068] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted heterocyclyl group, such as a substituted or unsubstituted 3-6 membered heterocyclyl group, a substituted or unsubstituted 3-4 membered heterocyclyl group, a substituted or unsubstituted 4-5 membered heterocyclyl group, or a substituted or unsubstituted 5-6 membered heterocyclyl group. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced by a 5-8 membered heterocyclyl group having 1 to 4 ring heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced by a 6 membered heterocyclyl group having 1 to 3 ring heteroatoms selected from the group consisting of nitrogen and oxygen. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced by piperidine, piperidine, or piperidine. or morpholine displacement.
[0069] In certain embodiments, L2 comprises at least one instance of a substituted or unsubstituted arylene group, such as a substituted or unsubstituted phenylene group. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced by an optionally substituted phenyl group.
[0070] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted heteroaryl, such as substituted or unsubstituted 5-6 membered heteroaryl.
[0071] In certain embodiments, L2 is an unsubstituted hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently substituted with -NR a1 - permutation, and R a1 Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 an alkyl group or a nitrogen protecting group, or, as the case may be, R a1Two instances of are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic ring or a substituted or unsubstituted heteroaryl ring. In certain embodiments, R a1 At least one example of is hydrogen. In certain embodiments, R a1 At least one example is a substituted or unsubstituted C 1-6 In certain embodiments, R a1 At least one example is a nitrogen protecting group (e.g., benzyl (Bn), tert-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)).
[0072] In certain embodiments, L2 is an optionally substituted C 1-45 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 In certain embodiments, L2 is an unsubstituted C 1-45 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 In certain embodiments, L2 is an optionally substituted C 1-24 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 In certain embodiments, L2 is an unsubstituted C 1-24 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 In certain embodiments, L2 is an optionally substituted C 1-20 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1are independently hydrogen, substituted or unsubstituted C 1-6 In certain embodiments, L2 is an unsubstituted C 1-20 A hydrocarbon chain, wherein one or more of the chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O-, -NR a1 -, -S- or cyclic moiety replacement, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 In certain embodiments, L2 is an optionally substituted C 1-30 A hydrocarbon chain, wherein one or more atoms of the hydrocarbon chain are independently connected by -O- or -NR a1 -substituted. In certain embodiments, L2 is an unsubstituted C 1-30 A hydrocarbon chain, wherein one or more atoms of the hydrocarbon chain are independently connected by -O- or -NR a1 -substituted. In certain embodiments, L2 is an unsubstituted C 1-30 In certain embodiments, L2 is an unsubstituted C 1-26 A hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O- or -NR a1 -substituted. In certain embodiments, L2 is an unsubstituted C 1-20 In certain embodiments, L2 is an unsubstituted C 5-26 A hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O- or -NR a1 -substituted. In certain embodiments, L2 is an unsubstituted C 5-26 In certain embodiments, L2 is an unsubstituted C 5-20 A hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O- or -NR a1 -substituted. In certain embodiments, L2 is an unsubstituted C 5-20 A hydrocarbon chain, wherein one or more atoms of the hydrocarbon chain are independently connected by -O- or -NR a1 -substituted. In certain embodiments, L2 is an unsubstituted C 5-15 A hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O- or -NR a1 -substituted. In certain embodiments, L2 is an unsubstituted C 15-20 A hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O- or -NR a1 -substituted. In certain embodiments, L2 is an unsubstituted C20-25 A hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently connected by -C(=O)-, -O- or -NR a1 -substituted. In certain embodiments, L2 is substituted or unsubstituted C 1-45 In certain embodiments, L2 is a substituted or unsubstituted C 5-40 In certain embodiments, one or more chain atoms of the hydrocarbon chain of L2 are independently -C(=O)-, -O-, -S-, -NR a1 In certain embodiments, one or more chain atoms of the hydrocarbon chain of L2 are independently replaced by -C(=O)-, -O- or -NR a1 - permutation, where R a1 are independently hydrogen, substituted or unsubstituted C 1-6 In certain embodiments, L2 is an unsubstituted C 1-26 A hydrocarbon chain wherein at least one of the chain atoms of the hydrocarbon chain is independently replaced by -O-. The cyclic moiety herein refers to a cycloalkyl group or a heterocycloalkyl group, such as
[0073] In certain embodiments, L2 is an all-carbon substituted or unsubstituted C 1-45 In certain embodiments, L2 is an all-carbon substituted or unsubstituted C 1-30 In certain embodiments, L2 is an all-carbon substituted or unsubstituted C 1-26 In certain embodiments, L2 is an all-carbon substituted or unsubstituted C 1-24 In certain embodiments, L2 is an all-carbon substituted or unsubstituted C 1-20 In certain embodiments, L2 is an all-carbon substituted or unsubstituted C 1-20 Hydrocarbon chain.
[0074] In some embodiments, L2 is In certain embodiments, L2 comprises a moiety wherein g is 1, 2, 3, 4, 5, or 6. In certain embodiments, g is 1. In certain embodiments, g is 2. In certain embodiments, g is 3. In certain embodiments, g is 4. In certain embodiments, g is 5. In certain embodiments, g is 6.
[0075] In certain embodiments, L2 includes the moiety -NHC(=O)-.
[0076] In certain embodiments, L2 comprises the moiety -NH-.
[0077] Examples of L2 of the present invention include, but are not limited to:
[0078]
[0079] In certain embodiments, L2 has the formula:
[0080]
[0081] In certain embodiments, L2 has the formula:
[0082] In certain embodiments, L2 has the formula:
[0083] wherein g is 1, 2, 3, 4 or 5; h is 0, 1, 2, 3, 4 or 5; and f is 1, 2, 3, 4, 5, 6, 7 or 8.
[0084] In certain embodiments, L2 has the formula:
[0085] wherein g is 1, 2, 3, 4, 5, 6, 7 or 8; and f is 1, 2, 3, 4, 5, 6, 7 or 8.
[0086] In certain embodiments, L2 has the formula:
[0087] wherein g is 1, 2, 3, 4, 5, 6, 7 or 8.
[0088] In certain embodiments, L2 has the formula:
[0089] wherein g is 1, 2, 3, 4, 5, 6, 7 or 8; and f is 1, 2, 3, 4, 5, 6, 7 or 8.
[0090] In certain embodiments, L2 has the formula:
[0091] wherein g is 1, 2, 3, 4, 5, 6, 7 or 8; and f is 1, 2, 3, 4, 5, 6, 7 or 8.
[0092] In certain embodiments, L2 has the formula: wherein g is 1, 2, 3, 4, 5, 6, 7 or 8.
[0093] In certain embodiments, the compounds of the invention have any of the following structures,
[0094]
[0095] Wherein in Formula I-1, R 3 ' is H or C 1-6Alkyl; Y1 is CH2 or L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L3 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; wherein Z and U are not heteroatoms at the same time; Q is CH or N; K is CH or N; wherein Q and K are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2;
[0096] In Formula II-1, R 2 ' is independently selected at each occurrence from the group consisting of: H, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Y1 is CH2 or L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L3 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; wherein Z and U are not heteroatoms at the same time; Q is CH or N; K is CH or N; wherein Q and K are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2;
[0097] In formula III-1, L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L3 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; wherein Z and U are not heteroatoms at the same time; Q is CH or N; K is CH or N; wherein Q and K are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2;
[0098] In Formula IV-1, R 3 ' is H or C 1-6 Alkyl; Y1 is CH2 or L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L3 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; T is CH or N; wherein only one of U, Z and T is a heteroatom; Q is CH or N; K is CH or N; wherein Q and K are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; X is CR 6 or N; Y is CR 6 or N; wherein one of X and Y is N and the other is CR 6 ; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl and / or halo substituents;
[0099] In formula V-1, R 2 ' is independently selected at each occurrence from the group consisting of: H, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Y1 is CH2 or L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L3 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl, or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50 a hydrocarbon chain; Z is C or N; U is O, S or CH; T is CH or N; wherein only one of U, Z and T is a heteroatom; Q is CH or N; K is CH or N; wherein Q and K are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; X is CR 6 or N; Y is CR 6 or N; wherein one of X and Y is N and the other is CR 6 ; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl and / or halo substituents;
[0100] In Formula VI-1, L1 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, -NR-, -O- or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted C 1-50a hydrocarbon chain; Z is C or N; U is O, S or CH; T is CH or N; wherein only one of U, Z and T is a heteroatom; Q is CH or N; K is CH or N; wherein Q and K are not N at the same time; R"' is independently selected from the group consisting of H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 alkoxy and halogen; k is 0, 1, 2 or 3; R' is independently selected from the group consisting of H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 alkoxy; m is 0, 1, 2, 3 or 4; R" is independently selected from the group consisting of H, halo, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkyl, C 3-6 Cycloalkylamino and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; X is CR 6 or N; Y is CR 6 or N; wherein one of X and Y is N and the other is CR 6 ; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl groups and / or halogen groups are substituted.
[0101] In certain embodiments, the compound of formula I-1 has the following formula 1, 5, 6, 8, 10 or 13,
[0102]
[0103]
[0104] One embodiment of the present invention is a compound of formula 1, wherein R' is H, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, CF3, CCl3, methoxy or ethoxy, more preferably H, CF3 or methoxy.
[0105] One embodiment of the present invention is a compound of formula 1, wherein m is 0, 1, 2, 3 or 4, preferably 0 or 1.
[0106] One embodiment of the present invention is a compound of formula 1, wherein R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino and C 3-5 The heterocycloalkyl group is preferably H, F, Cl, NH2, methoxy, ethoxy, methylamino, dimethylamino, ethylamino, diethylamino, cyclopropyl, cyclobutyl or cyclopentyl, and more preferably H, F, dimethylamino or cyclopropyl.
[0107] One embodiment of the present invention is a compound of formula 1, wherein n is 0, 1 or 2, preferably 0 or 1.
[0108] One embodiment of the present invention is a compound of formula 1, wherein R'' is H, OH or halogen, preferably H, OH, F or Cl, more preferably H.
[0109] One embodiment of the present invention is a compound of formula 1, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
[0110] One embodiment of the present invention is a compound of formula 1, wherein R 1 ' is O, NH,
[0111] One embodiment of the present invention is a compound of formula 1, wherein A is O, NH, Preferably O or
[0112] One embodiment of the present invention is a compound of formula 1, wherein m2 is 2, 3, 4 or 6, preferably 2 or 6.
[0113] One embodiment of the present invention is a compound of formula 1, wherein R 3 ' is H or C 1-3 The alkyl group is preferably H or methyl, and more preferably H.
[0114] One embodiment of the present invention is a compound of formula 1, which has a structure as shown in formula 1-1,
[0115]
[0116] In formula 1-1, R 3 ' is H or C 1-3 Alkyl; Y1 is CH2 or A is O, NH, m2 is 1, 2, 3, 4, 5, 6 and 7; R 1 ' is O, NH, U is O, S or CH; Z is C or N; U and Z are not heteroatoms at the same time; R' is H, C 1-3 Haloalkyl or C 1-3 Alkoxy; R" is H, F, Cl, OH, NH2, C 1-3 Alkoxy, methylamino, dimethylamino, diethylamino or cyclopropylamino; n is 0, 1 or 2.
[0117] One embodiment of the present invention is a compound of formula 1-1, wherein m2 is 2, 3, 4 or 6, preferably 2 or 6.
[0118] One embodiment of the present invention is a compound of formula 1-1, wherein R 3 ' is H or methyl.
[0119] One embodiment of the present invention is a compound of formula 1-1, wherein A is O or
[0120] One embodiment of the present invention is a compound of formula 1-1, wherein R 1 ' is O, NH or
[0121] One embodiment of the present invention is a compound of formula 1-1, wherein Z is N, and U is CH.
[0122] One embodiment of the present invention is a compound of formula 1-1, wherein Z is C, and U is S or O.
[0123] One embodiment of the present invention is a compound of formula 1-1, wherein R" is H, F, Cl, OH, NH2, methoxy, methylamino, dimethylamino, diethylamino, cyclopropyl or cyclopropylamino, preferably H, F, methylamino, dimethylamino or cyclopropylamino.
[0124] One embodiment of the present invention is a compound of formula 1-1, wherein R' is H, C 1-3 Fluoroalkyl, methoxy or ethoxy, preferably R' is H, methoxy or CF3.
[0125] One embodiment of the present invention is a compound of formula 5, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0126] One embodiment of the present invention is a compound of formula 5, wherein A is O, NH or Preferably O.
[0127] One embodiment of the present invention is a compound of formula 5, wherein m4 is 0, 1, 2 or 3, preferably 0 or 3.
[0128] One embodiment of the present invention is a compound of formula 5, wherein m5 is 0, 1, 2 or 3, preferably 0 or 1.
[0129] One embodiment of the present invention is a compound of formula 5, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 3 or 5.
[0130] One embodiment of the present invention is a compound of formula 5, wherein R 1 ' is O, NH or
[0131] One embodiment of the present invention is a compound of formula 5, wherein R'' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0132] One embodiment of the present invention is a compound of formula 5, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
[0133] One embodiment of the present invention is a compound of formula 5, wherein Z is C, and U is O or S.
[0134] One embodiment of the present invention is a compound of formula 5, wherein Z is N, and U is CH.
[0135] One embodiment of the present invention is a compound of formula 5, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0136] One embodiment of the present invention is a compound of formula 5, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
[0137] One embodiment of the present invention is a compound of formula 5, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, cyclopropyl or dimethylamino, and more preferably H, F, CF3, cyclopropyl, cyclopropylamino or dimethylamino.
[0138] One embodiment of the present invention is a compound of formula 5, wherein n is 0, 1 or 2, preferably 0 or 1.
[0139] One embodiment of the present invention is a compound of formula 5, which has a structure as shown in formula 5-1,
[0140]
[0141] In formula 5-1, R 3 ' is H or C 1-3 Alkyl; Y1 is CH2 or A is O, NH, m5 is 0 or 1; m4 is 0, 1, 2, 3 or 4; m3 is 1, 2, 3, 4, 5 or 6; R 1 ' is O, NH, Z is C or N; U is O, S or CH; Z and U are not heteroatoms at the same time; R'' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen; R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino and C 3-5 Heterocycloalkyl; n is 0, 1 or 2.
[0142] One embodiment of the present invention is a compound of formula 5-1, wherein A is O.
[0143] One embodiment of the present invention is a compound of formula 5-1, wherein m5 is 0 or 1.
[0144] One embodiment of the present invention is a compound of formula 5-1, wherein m4 is 0 or 3.
[0145] One embodiment of the present invention is a compound of formula 5-1, wherein m3 is 3 or 5.
[0146] One embodiment of the present invention is a compound of formula 5-1, wherein R 1 ' is O, NH or
[0147] One embodiment of the present invention is a compound of formula 5-1, wherein Z is C, and U is O or S.
[0148] One embodiment of the present invention is a compound of formula 5-1, wherein Z is N, and U is CH.
[0149] One embodiment of the present invention is a compound of formula 5-1, wherein R' is H, halogen, C 1-3 Alkyl, C 1-3 Fluoroalkyl or C 1-3The alkoxy group is preferably H, methyl, CF3, methyl or methoxy, more preferably H or CF3.
[0150] One embodiment of the present invention is a compound of formula 5-1, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, CF3, amino, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, and more preferably H, F, CF3, dimethylamino, cyclopropylamino or cyclopropyl.
[0151] One embodiment of the present invention is a compound of formula 6, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0152] One embodiment of the present invention is a compound of formula 6, wherein A is O, NH or Preferred is O or NH.
[0153] One embodiment of the present invention is a compound of formula 6, wherein m2 is 1, 2, 3, 4, 5, 6 or 7, preferably 2 or 6.
[0154] One embodiment of the present invention is a compound of formula 6, wherein R 1 ' is O, NH or Preferred is O or NH.
[0155] One embodiment of the present invention is a compound of formula 6, wherein Z is C or N, and U is O, S or CH, wherein Z and U are not heteroatoms at the same time; preferably, Z is C and U is S.
[0156] One embodiment of the present invention is a compound of formula 6, wherein R'' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0157] One embodiment of the present invention is a compound of formula 6, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0158] One embodiment of the present invention is a compound of formula 6, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
[0159] One embodiment of the present invention is a compound of formula 6, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, and more preferably H, F, CF3, dimethylamino, cyclopropyl or cyclopropylamino.
[0160] One embodiment of the present invention is a compound of formula 6, wherein n is 0 or 1.
[0161] One embodiment of the present invention is a compound of formula 6, which has a structure as shown in formula 6-1,
[0162]
[0163] In formula 6-1, R 3 ' is H or C 1-3 Alkyl; Y1 is CH2 or A is O, NH, m2 is 1, 2, 3, 4, 5, 6 or 7; R 1 ' is O, NH, R"' is H, OH, C 1-3 Alkyl, C 1-3 alkoxy or halogen; k is 0, 1, 2 or 3; Z is C or N; U is O, S or CH; wherein Z and U are not heteroatoms at the same time; R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl; n is 0, 1 or 2.
[0164] One embodiment of the present invention is a compound of formula 6-1, wherein R 3 ' is H or methyl.
[0165] One embodiment of the present invention is a compound of formula 6-1, wherein A is O or NH.
[0166] One embodiment of the present invention is a compound of formula 6-1, wherein m2 is 2 or 6.
[0167] One embodiment of the present invention is a compound of formula 6-1, wherein R 1 ' is O or NH.
[0168] One embodiment of the present invention is a compound of formula 6-1, wherein R' is H or CF3.
[0169] One embodiment of the present invention is a compound of formula 6-1, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
[0170] One embodiment of the present invention is a compound of formula 6-1, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl is preferably H, F, CF3, methoxy, methyl, dimethylamino, cyclopropyl, cyclopropylamino or methylamino, more preferably H, CF3, F, dimethylamino, cyclopropyl or cyclopropylamino, and most preferably H, dimethylamino, cyclopropyl or cyclopropylamino.
[0171] One embodiment of the present invention is a compound of formula 6-1, wherein n is 0 or 1.
[0172] One embodiment of the present invention is a compound of formula 6-1, wherein R" is substituted at a position adjacent to the N atom.
[0173] One embodiment of the present invention is a compound of formula 8, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0174] One embodiment of the present invention is a compound of formula 8, wherein Y1 is CH2 or Preferred is CH2.
[0175] One embodiment of the present invention is a compound of formula 8, wherein A is O, NH, Preferably O.
[0176] One embodiment of the present invention is a compound of formula 8, wherein m2 is 1, 2, 3 or 4, preferably 2.
[0177] One embodiment of the present invention is a compound of formula 8, wherein R 1 ' is O, NH, Preferably O.
[0178] One embodiment of the present invention is a compound of formula 8, wherein R'' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0179] One embodiment of the present invention is a compound of formula 8, wherein k is 0 or 1.
[0180] One embodiment of the present invention is a compound of formula 8, wherein Z is C or N; U is O, S or CH; wherein Z and U are not heteroatoms at the same time; preferably Z is N and U is CH; preferably Z is C and U is S.
[0181] One embodiment of the present invention is a compound of formula 8, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0182] One embodiment of the present invention is a compound of formula 8, wherein m is 0, 1 or 2.
[0183] One embodiment of the present invention is a compound of formula 8, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, and more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
[0184] One embodiment of the present invention is a compound of formula 8, wherein n is 0, 1 or 2.
[0185] One embodiment of the present invention is a compound of formula 8, which is
[0186] One embodiment of the present invention is a compound of formula 10, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0187] One embodiment of the present invention is a compound of formula 10, wherein Y1 is CH2 or Preferred is CH2.
[0188] One embodiment of the present invention is a compound of formula 10, wherein A is O, NH, Preferably
[0189] One embodiment of the present invention is a compound of formula 10, wherein m5 is 0 or 1.
[0190] One embodiment of the present invention is a compound of formula 10, wherein m4 is 0 or 1.
[0191] One embodiment of the present invention is a compound of formula 10, wherein m3 is 1, 2, 3, 4 or 5, preferably 4.
[0192] One embodiment of the present invention is a compound of formula 10, wherein R 1 ' is O, NH, Preferably O.
[0193] One embodiment of the present invention is a compound of formula 10, wherein R'' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0194] One embodiment of the present invention is a compound of formula 10, wherein k is 0 or 1.
[0195] One embodiment of the present invention is a compound of formula 10, wherein Z is C, and U is S or O.
[0196] One embodiment of the present invention is a compound of formula 10, wherein Z is N, and U is CH.
[0197] One embodiment of the present invention is a compound of formula 10, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0198] One embodiment of the present invention is a compound of formula 10, wherein m is 0 or 1.
[0199] One embodiment of the present invention is a compound of formula 10, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, and more preferably H, F or CF3.
[0200] One embodiment of the present invention is a compound of formula 10, wherein n is 0 or 1.
[0201] One embodiment of the present invention is a compound of formula 13, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0202] One embodiment of the present invention is a compound of formula 13, wherein Y1 is CH2 or Preferred is CH2.
[0203] One embodiment of the present invention is a compound of formula 13, wherein A is O, NH, Preferably
[0204] One embodiment of the present invention is a compound of formula 13, wherein m2 is 1, 2, 3 or 4, preferably 1.
[0205] One embodiment of the present invention is a compound of formula 13, wherein R 1 ' is O, NH, Preferred is NH.
[0206] One embodiment of the present invention is a compound of formula 13, wherein R'' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0207] One embodiment of the present invention is a compound of formula 13, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
[0208] One embodiment of the present invention is a compound of formula 13, wherein Z is C, and U is S or O.
[0209] One embodiment of the present invention is a compound of formula 13, wherein Z is N, and U is CH.
[0210] One embodiment of the present invention is a compound of formula 13, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0211] One embodiment of the present invention is a compound of formula 13, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
[0212] One embodiment of the present invention is a compound of formula 13, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H, F, CF3, dimethylamino, cyclopropyl or cyclopropylamino, and most preferably dimethylamino.
[0213] One embodiment of the present invention is a compound of formula 13, wherein n is 0, 1 or 2, preferably 0 or 1.
[0214] One embodiment of the compound of formula II-1 has the following formula 3,
[0215]
[0216] One embodiment of the present invention is a compound of formula 3, wherein R 2 ' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamine or NH2, preferably H, OH or NH2.
[0217] One embodiment of the present invention is a compound of formula 3, wherein m6 is 0, 1, 2 or 3, preferably 0 or 1.
[0218] One embodiment of the present invention is a compound of formula 3, wherein R 1 ' is O or NH.
[0219] One embodiment of the present invention is a compound of formula 3, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy, preferably H, halogen or C 1-3 The fluoroalkyl group is more preferably H or F.
[0220] One embodiment of the present invention is a compound of formula 3, wherein m is 0, 1, 2, 3 or 4, preferably 0 or 1.
[0221] One embodiment of the present invention is a compound of formula 3, wherein R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3The alkylamino group is preferably H, halogen, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, and more preferably H, F or dimethylamino.
[0222] One embodiment of the present invention is a compound of formula 3, wherein n is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0223] One embodiment of the present invention is a compound of formula 3, wherein Z is C, and U is O or S.
[0224] One embodiment of the present invention is a compound of formula 3, wherein Z is N, and U is CH.
[0225] One embodiment of the present invention is a compound of formula 3, wherein R'' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen, preferably H, F, methyl or methoxy, more preferably H.
[0226] One embodiment of the present invention is a compound of formula 3, which has a structure as shown in formula 3-1,
[0227]
[0228] In formula 3-1, R 2 ' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino or NH2; m6 is 0, 1, 2 or 3; Y1 is CH2 or R 1 ' is O, NH, Z is C or N; U is O, S or CH; Z and U are not heteroatoms at the same time; R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3 Alkylamino; n is 0, 1 or 2.
[0229] One embodiment of the present invention is a compound of formula 3-1, wherein R 2 ' is H, NH2 or OH.
[0230] One embodiment of the present invention is a compound of formula 3-1, wherein m6 is 0 or 1.
[0231] One embodiment of the present invention is a compound of formula 3-1, wherein when m6 is 1, R 2 'The following positions in the phenyl group are substituted:
[0232] One embodiment of the present invention is a compound of formula 3-1, wherein R 1 ' is O or NH.
[0233] One embodiment of the present invention is a compound of formula 3-1, wherein R" is F, dimethylamino, methylamino, cyclopropyl or cyclopropylamino.
[0234] One embodiment of the present invention is a compound of formula 3-1, wherein n is 0, 1 or 2.
[0235] One embodiment of the compound of formula III-1 has the following formula 15,
[0236]
[0237] One embodiment of the present invention is a compound of formula 15, wherein m2 is 1, 2, 3, 4, 5, 6 or 7, preferably 1, 2, 3, 4, 5 or 6, and more preferably 2 or 5.
[0238] One embodiment of the present invention is a compound of formula 15, wherein R 1 ' is O, NH, Preferred is O or NH.
[0239] One embodiment of the present invention is a compound of formula 15, wherein R'' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen, preferably H, F, methyl or methoxy, more preferably H.
[0240] One embodiment of the present invention is a compound of formula 15, wherein Z is C, and U is O or S.
[0241] One embodiment of the present invention is a compound of formula 15, wherein Z is N, and U is CH.
[0242] One embodiment of the present invention is a compound of formula 15, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy, preferably H, halogen or C 1-3 The fluoroalkyl group is more preferably H, CF3 or F.
[0243] One embodiment of the present invention is a compound of formula 15, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0244] One embodiment of the present invention is a compound of formula 15, wherein R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3The alkylamino group is preferably H, halogen, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F, methylamino, cyclopropylamino or dimethylamino, and most preferably H or dimethylamino.
[0245] One embodiment of the present invention is a compound of formula 15, wherein n is 0, 1 or 2, preferably 0 or 1.
[0246] An embodiment of the compound of formula IV-1 has the following formula 2, 7, 9, 11, 12 or 14,
[0247]
[0248]
[0249] One embodiment of the present invention is a compound of formula 2, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0250] One embodiment of the present invention is a compound of formula 2, wherein Y1 is CH2 or
[0251] One embodiment of the present invention is a compound of formula 2, wherein A is O, NH, Preferably O.
[0252] One embodiment of the present invention is a compound of formula 2, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 6.
[0253] One embodiment of the present invention is a compound of formula 2, wherein R 1 ' is O, NH, Preferred is NH.
[0254] One embodiment of the present invention is a compound of formula 2, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, and more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
[0255] One embodiment of the present invention is a compound of formula 2, wherein n is 0, 1 or 2, preferably 0 or 1.
[0256] One embodiment of the present invention is a compound of formula 2, wherein R' is H, halogen, OH, C1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0257] One embodiment of the present invention is a compound of formula 2, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0258] One embodiment of the present invention is a compound of formula 2, wherein Z is C, U is O or S, and W is CH.
[0259] One embodiment of the present invention is a compound of formula 2, wherein Z is N, U is CH, and W is CH.
[0260] One embodiment of the present invention is a compound of formula 2, wherein Z is C, W is N, and U is CH.
[0261] One embodiment of the present invention is a compound of formula 2, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0262] One embodiment of the present invention is a compound of formula 2, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0263] One embodiment of the present invention is a compound of formula 7, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0264] One embodiment of the present invention is a compound of formula 7, wherein Y1 is CH2 or
[0265] One embodiment of the present invention is a compound of formula 7, wherein A is O, NH, Preferably O.
[0266] One embodiment of the present invention is a compound of formula 7, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
[0267] One embodiment of the present invention is a compound of formula 7, wherein R 1 ' is O, NH, Preferred is NH.
[0268] One embodiment of the present invention is a compound of formula 7, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, and more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
[0269] One embodiment of the present invention is a compound of formula 7, wherein n is 0, 1 or 2, preferably 0 or 1.
[0270] One embodiment of the present invention is a compound of formula 7, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0271] One embodiment of the present invention is a compound of formula 7, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0272] One embodiment of the present invention is a compound of formula 7, wherein Z is C, U is O or S, and W is CH.
[0273] One embodiment of the present invention is a compound of formula 7, wherein Z is N, U is CH, and W is CH.
[0274] One embodiment of the present invention is a compound of formula 7, wherein Z is C, W is N, and U is CH.
[0275] One embodiment of the present invention is a compound of formula 7, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0276] One embodiment of the present invention is a compound of formula 7, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0277] One embodiment of the present invention is a compound of formula 9, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0278] One embodiment of the present invention is a compound of formula 9, wherein Y1 is CH2 or
[0279] One embodiment of the present invention is a compound of formula 9, wherein A is O, NH, Preferably O.
[0280] One embodiment of the present invention is a compound of formula 9, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
[0281] One embodiment of the present invention is a compound of formula 9, wherein R 1 ' is O, NH, Preferred is NH.
[0282] One embodiment of the present invention is a compound of formula 9, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, and more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
[0283] One embodiment of the present invention is a compound of formula 9, wherein n is 0, 1 or 2, preferably 0 or 1.
[0284] One embodiment of the present invention is a compound of formula 9, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0285] One embodiment of the present invention is a compound of formula 9, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0286] One embodiment of the present invention is a compound of formula 9, wherein Z is C, U is O or S, and W is CH.
[0287] One embodiment of the present invention is a compound of formula 9, wherein Z is N, U is CH, and W is CH.
[0288] One embodiment of the present invention is a compound of formula 9, wherein Z is C, W is N, and U is CH.
[0289] One embodiment of the present invention is a compound of formula 9, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0290] One embodiment of the present invention is a compound of formula 9, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0291] One embodiment of the present invention is a compound of formula 11, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0292] One embodiment of the present invention is a compound of formula 11, wherein Y1 is CH2 or
[0293] One embodiment of the present invention is a compound of formula 11, wherein A is O, NH, Preferably O.
[0294] One embodiment of the present invention is a compound of formula 11, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
[0295] One embodiment of the present invention is a compound of formula 11, wherein R 1 ' is O, NH, Preferred is NH.
[0296] One embodiment of the present invention is a compound of formula 11, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, and more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
[0297] One embodiment of the present invention is a compound of formula 11, wherein n is 0, 1 or 2, preferably 0 or 1.
[0298] One embodiment of the present invention is a compound of formula 11, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0299] One embodiment of the present invention is a compound of formula 11, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0300] One embodiment of the present invention is a compound of formula 11, wherein Z is C, U is O or S, and W is CH.
[0301] One embodiment of the present invention is a compound of formula 11, wherein Z is N, U is CH, and W is CH.
[0302] One embodiment of the present invention is a compound of formula 11, wherein Z is C, W is N, and U is CH.
[0303] One embodiment of the present invention is a compound of formula 11, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0304] One embodiment of the present invention is a compound of formula 11, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0305] One embodiment of the present invention is a compound of formula 12, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0306] One embodiment of the present invention is a compound of formula 12, wherein Y1 is CH2 or Preferred is CH2.
[0307] One embodiment of the present invention is a compound of formula 12, wherein A is O, NH, Preferably O.
[0308] One embodiment of the present invention is a compound of formula 12, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 2 or 3.
[0309] One embodiment of the present invention is a compound of formula 12, wherein m4 is 0 or 1, 2 or 3, preferably 0 or 3.
[0310] One embodiment of the present invention is a compound of formula 12, wherein m5 is 0 or 1, 2 or 3, preferably 0 or 1.
[0311] One embodiment of the present invention is a compound of formula 12, wherein R 1 ' is O, NH, Preferred is NH.
[0312] One embodiment of the present invention is a compound of formula 12, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, and more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
[0313] One embodiment of the present invention is a compound of formula 12, wherein n is 0, 1 or 2, preferably 0 or 1.
[0314] One embodiment of the present invention is a compound of formula 12, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0315] One embodiment of the present invention is a compound of formula 12, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0316] One embodiment of the present invention is a compound of formula 12, wherein Z is C, U is O or S, and W is CH.
[0317] One embodiment of the present invention is a compound of formula 12, wherein Z is N, U is CH, and W is CH.
[0318] One embodiment of the present invention is a compound of formula 12, wherein Z is C, W is N, and U is CH.
[0319] One embodiment of the present invention is a compound of formula 12, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0320] One embodiment of the present invention is a compound of formula 12, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0321] One embodiment of the present invention is a compound of formula 14, wherein R 3 ' is H or C 1-3 Alkyl, preferably H or methyl.
[0322] One embodiment of the present invention is a compound of formula 14, wherein Y1 is CH2 or Preferred is CH2.
[0323] One embodiment of the present invention is a compound of formula 14, wherein A is O, NH, Preferably O.
[0324] One embodiment of the present invention is a compound of formula 14, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 2, 3 or 4.
[0325] One embodiment of the present invention is a compound of formula 14, wherein m4 is 0, 1, 2, 3 or 4, preferably 0 or 3.
[0326] One embodiment of the present invention is a compound of formula 14, wherein m5 is 0 or 1, 2 or 3, preferably 0 or 1.
[0327] One embodiment of the present invention is a compound of formula 14, wherein R 1 ' is O, NH, Preferably
[0328] One embodiment of the present invention is a compound of formula 14, wherein R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 The heterocycloalkyl group is preferably H, F, OH, NH2, methyl, methoxy, CF3, CCl3, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, and more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
[0329] One embodiment of the present invention is a compound of formula 14, wherein n is 0, 1 or 2, preferably 0 or 1.
[0330] One embodiment of the present invention is a compound of formula 14, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The alkoxy group is preferably H, F, CF3, CCl3, methyl or methoxy, more preferably H or CF3.
[0331] One embodiment of the present invention is a compound of formula 14, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0332] One embodiment of the present invention is a compound of formula 14, wherein Z is C, U is O or S, and W is CH.
[0333] One embodiment of the present invention is a compound of formula 14, wherein Z is N, U is CH, and W is CH.
[0334] One embodiment of the present invention is a compound of formula 14, wherein Z is C, W is N, and U is CH.
[0335] One embodiment of the present invention is a compound of formula 14, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0336] One embodiment of the present invention is a compound of formula 14, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0337] One embodiment of the compound of formula V-1 has the following formula 4,
[0338]
[0339] One embodiment of the present invention is a compound of formula 4, wherein R 2 ' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamine or NH2, preferably H, OH or NH2.
[0340] One embodiment of the present invention is a compound of formula 4, wherein m6 is 0, 1, 2 or 3, preferably 0 or 1. One embodiment of the present invention is a compound of formula 4, wherein R 1 ' is O, NH, Preferred is O or NH.
[0341] One embodiment of the present invention is a compound of formula 4, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy, preferably H, halogen or C 1-3 The fluoroalkyl group is more preferably H or F.
[0342] One embodiment of the present invention is a compound of formula 4, wherein m is 0, 1, 2, 3 or 4, preferably 0 or 1.
[0343] One embodiment of the present invention is a compound of formula 4, wherein R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3 The alkylamino group is preferably H, halogen, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, and more preferably H, F or dimethylamino.
[0344] One embodiment of the present invention is a compound of formula 4, wherein n is 0, 1 or 2, preferably 0 or 1.
[0345] One embodiment of the present invention is a compound of formula 4, wherein Z is C, U is O or S, and W is CH.
[0346] One embodiment of the present invention is a compound of formula 4, wherein Z is N, U is CH, and W is CH.
[0347] One embodiment of the present invention is a compound of formula 4, wherein Z is C, U is CH, and W is N.
[0348] One embodiment of the present invention is a compound of formula 4, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0349] One embodiment of the present invention is a compound of formula 4, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0350] One embodiment of the present invention is a compound of formula 4, which has a structure as shown in formula 4-1,
[0351]
[0352] In formula 4-1, R 2 ' is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino or NH2; Y1 is CH2 or
[0353] R 1 ' is O, NH, R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine or C 3-5 Heterocycloalkyl; n is 0, 1 or 2; R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; m is 0, 1 or 2; U is O or S; R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 alkoxy or halogen; k is 0, 1, 2, 3 or 4.
[0354] One embodiment of the present invention is a compound of formula 4-1, wherein R 1 'For NH.
[0355] One embodiment of the present invention is a compound of formula 4-1, wherein R" is H.
[0356] One embodiment of the present invention is a compound of formula 4-1, wherein R' is H.
[0357] One embodiment of the present invention is a compound of formula 4-1, wherein R 2 'For OH.
[0358] One embodiment of the present invention is a compound of formula 4-1, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0359] One embodiment of the present invention is a compound of formula 4, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0360] One embodiment of the present invention is a compound of formula 4, wherein U is S.
[0361] An embodiment of the compound of formula VI-1 has the following formula 16 or 17,
[0362]
[0363] One embodiment of the present invention is a compound of formula 16, wherein m2 is 1, 2, 3, 4, 5 or 6, preferably 2 or 5.
[0364] One embodiment of the present invention is a compound of formula 16, wherein R 1 ' is O, NH, Preferred is NH.
[0365] One embodiment of the present invention is a compound of formula 16, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy, preferably H, halogen or C 1-3 The fluoroalkyl group is more preferably H or F.
[0366] One embodiment of the present invention is a compound of formula 16, wherein m is 0, 1, 2, 3 or 4, preferably 0 or 1.
[0367] One embodiment of the present invention is a compound of formula 16, wherein R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3The alkylamino group is preferably H, halogen, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, and more preferably H, F or dimethylamino.
[0368] One embodiment of the present invention is a compound of formula 16, wherein n is 0, 1 or 2, preferably 0 or 1.
[0369] One embodiment of the present invention is a compound of formula 16, wherein Z is C, U is O or S, and W is CH.
[0370] One embodiment of the present invention is a compound of formula 16, wherein Z is N, U is CH, and W is CH.
[0371] One embodiment of the present invention is a compound of formula 16, wherein Z is C, U is CH, and W is N.
[0372] One embodiment of the present invention is a compound of formula 16, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0373] One embodiment of the present invention is a compound of formula 16, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0374] One embodiment of the present invention is a compound of formula 17, wherein m2 is 1, 2, 3, 4, 5 or 6, preferably 2 or 5.
[0375] One embodiment of the present invention is a compound of formula 17, wherein R 1 ' is O, NH, Preferred is NH.
[0376] One embodiment of the present invention is a compound of formula 17, wherein R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy, preferably H, halogen or C 1-3 The fluoroalkyl group is more preferably H or F.
[0377] One embodiment of the present invention is a compound of formula 17, wherein m is 0, 1, 2, 3 or 4, preferably 0 or 1.
[0378] One embodiment of the present invention is a compound of formula 17, wherein R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3The alkylamino group is preferably H, halogen, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, and more preferably H, F or dimethylamino.
[0379] One embodiment of the present invention is a compound of formula 17, wherein n is 0, 1 or 2, preferably 0 or 1.
[0380] One embodiment of the present invention is a compound of formula 17, wherein Z is C, U is O or S, and W is CH.
[0381] One embodiment of the present invention is a compound of formula 17, wherein Z is N, U is CH, and W is CH.
[0382] One embodiment of the present invention is a compound of formula 17, wherein Z is C, U is CH, and W is N.
[0383] One embodiment of the present invention is a compound of formula 17, wherein R'' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0384] One embodiment of the present invention is a compound of formula 17, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, and more preferably 0 or 1.
[0385] Some embodiments of the present invention are compounds having the structures depicted in Table 1.
[0386] Table 1.
[0387]
[0388]
[0389]
[0390]
[0391]
[0392]
[0393]
[0394]
[0395]
[0396]
[0397]
[0398]
[0399]
[0400]
[0401]
[0402]
[0403]
[0404]
[0405] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols generally indicate similar components unless the context otherwise dictates. The illustrative alternatives described in the embodiments, drawings, and claims are not intended to be limiting. Other alternatives may be used and other changes may be made without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects generally described herein and illustrated in the drawings may be configured, replaced, combined, and designed in a wide variety of different configurations, all of which are expressly contemplated and form a part of the present application.
[0406] One embodiment is a compound, wherein the compound is isotopically labeled or radioactively labeled. One embodiment is a solvate, hydrate, salt or ester or compound of the present invention.
[0407] One aspect of the present invention is a composition comprising a compound of the present invention and a pharmaceutically acceptable excipient.
[0408] One aspect of the present invention is a method for adjunctive treatment of tauopathy in a subject, the method comprising administering an effective amount of a compound or composition of the present invention, wherein the compound or composition treats the subject.
[0409] In some embodiments, the tauopathy is a neurodegenerative tauopathy. In some embodiments, the tauopathy is selected from the group consisting of Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), Parkinson's disease (PD), Creutzfeldt-Jacob disease, Dementia pugilistica, Down's Syndrome, Gerstmann-Straussler-Scheinker disease, British dementia, Danish dementia, inclusion-body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam Parkinsonism-dementia complex, Non-Guamanian motor neuron disease with neurofibrillary tangles, neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcification, frontotetemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallevorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, Pallido-ponto-nigral degeneration, Pick's disease, progressive subcortical gliomatosisIn some embodiments, the tauopathy is Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or Pick's disease (PiD).
[0410] In some embodiments, according to any one of the methods described above, the method further comprises administering to the individual at least one additional therapy. In some embodiments, at least one additional therapy is selected from a neurological drug, an anti-Tau antibody, a Tau inhibitor, an anti-amyloid β antibody, a β-amyloid aggregation inhibitor, an anti-BACE1 antibody, and a BACE1 inhibitor.
[0411] In some embodiments, according to any of the methods described above, the individual is diagnosed as suffering from or at risk of suffering from a Tau protein-related disease. In some embodiments, the individual is diagnosed as suffering from or at risk of suffering from a tau protein disease selected from the group consisting of: Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick's disease (PiD).
[0412] In another aspect, a method for reducing pathological human Tau in a sample is provided herein. The method comprises the step of contacting the sample with a bispecific binder according to any one of the embodiments described above. In some embodiments, the pathological human Tau is from a tauopathy selected from the group consisting of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick's disease (PiD). In some embodiments, the pathological human Tau is Tau type 1A, type IB, type 11A, or type MB; misordered Tau; mis-disordered Tau; sarcosyl sodium insoluble Tau; extracellular Tau deposits; Tau aggregates; paired helical filaments; neurofibrillary lesions; or hyperphosphorylated forms of truncated Tau or full-length Tau. In some embodiments, the pathological human Tau is hyperphosphorylated and sarcosyl sodium insoluble Tau. In some embodiments, the sample is a brain sample, a cerebrospinal fluid sample, or a blood sample. In some embodiments, detecting comprises generating a reading comprising information about the presence of pathological human Tau in the sample. In some embodiments, the sample is from an individual and the method further comprises diagnosing whether the individual suffers from tauopathy or is likely to suffer from tauopathy based on the reading.
[0413] In another aspect, provided herein is a method of reducing the level of Tau protein in a subject having a Tau protein-related disease or at risk of suffering from a Tau protein-related disease, comprising administering to the subject a compound according to any one of the embodiments described above or a pharmaceutical composition according to any one of the embodiments described above, wherein a) the level of non-phosphorylated Tau protein, phosphorylated Tau protein and / or hyperphosphorylated Tau protein in the subject is reduced compared to the level of such proteins in the subject before administration of the compound; and / or b) the level of pathological Tau species in the subject is reduced compared to the level of the species in the subject before administration of the compound.
[0414] In another aspect, provided herein is a method of maintaining or improving cognitive memory ability or slowing down memory loss in an individual suffering from or at risk of suffering from a Tau-related disease, comprising administering to the individual a compound according to any one of the embodiments described above or a pharmaceutical composition according to any one of the embodiments described above.
[0415] In another aspect, provided herein is a method of inhibiting and / or reversing the propagation of Tau aggregation in a subject having or at risk of a Tau-related disease, comprising administering to the subject a compound according to any one of the embodiments described above or a pharmaceutical composition according to any one of the embodiments described above.
[0416] In another aspect, provided herein is a method of inhibiting and / or reversing Tau seeding in a subject having or at risk of a Tau-related disease, comprising administering to the subject a compound according to any one of the embodiments described above or a pharmaceutical composition according to any one of the embodiments described above.
[0417] definition
[0418] Unless otherwise defined, all technical terms, notations, and other scientific terms or technical nouns used herein are intended to have the meanings commonly understood by those skilled in the art to which this application relates. In some cases, for clarity and / or for ease of reference, terms with commonly understood meanings are defined herein, and the inclusion of such definitions herein should not necessarily be construed as representing a substantial difference from what is generally understood in the art. Those skilled in the art are fully aware of and routinely employ the various techniques and procedures described or referred to herein using conventional methods.
[0419] When a range of values is provided, it is understood that unless the context clearly indicates otherwise, each intermediate value between the upper and lower limits of the stated range (to one-tenth of the unit of the lower limit) and any other specified or intermediate value in the stated range are encompassed within the present invention. The upper and lower limits of such smaller ranges may be independently included in the smaller ranges and are also encompassed within the present invention, subject to any specific exclusive limitations within the stated range. When the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the present invention.
[0420] Certain ranges are presented herein with the term "about" preceding a numerical value. The term "about" is used herein to provide literal support for the exact numerical value that follows it, as well as numerical values that are close to or approximately the numerical value that follows the term. In determining whether a numerical value is close to or approximately a specifically recited numerical value, a close or approximate unrecited numerical value may be a numerical value that, in the context in which it is presented, provides a substantial equivalent to the specifically recited numerical value.
[0421] It should be understood that certain features of the present invention that are described in the context of different embodiments for the sake of clarity may also be provided in combination in a single embodiment. Conversely, various features of the present invention that are described in the context of a single embodiment for the sake of brevity may also be provided separately or in any suitable subcombination. All combinations of embodiments of the present invention are specifically encompassed by the present invention and disclosed herein, just as each combination is individually and explicitly disclosed herein. In addition, all subcombinations of the various embodiments and elements thereof are also specifically encompassed by the present invention and disclosed herein, just as each such subcombination is individually and explicitly disclosed herein. When a range of values is listed, it is intended to cover each value and subrange within the stated range. For example, "C 1-6 "Intended to cover C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 and C 5- 6.
[0422] "Alkyl" refers to a straight or branched chain saturated hydrocarbon group having a specified number of carbon atoms. In some embodiments, the alkyl group has 1 to 6 carbon atoms ("C 1-6 In some embodiments, the alkyl group has 1 to 5 carbon atoms ("C 1-5 In some embodiments, the alkyl group has 1 to 4 carbon atoms ("C 1-4 In some embodiments, the alkyl group has 1 to 3 carbon atoms ("C 1-3 In some embodiments, the alkyl group has 1 to 2 carbon atoms ("C 1-2 In some embodiments, the alkyl group has 1 carbon atom ("C1 alkyl"). In some embodiments, the alkyl group has 2 to 6 carbon atoms ("C 2-6 C 1-6 Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), t-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), t-pentyl (C5), and n-hexyl (C6).
[0423] "Alkenyl" refers to an alkyl group having one or more carbon-carbon double bonds at any position of the chain, which may be monosubstituted or polysubstituted, and may be monovalent, divalent or polyvalent. Examples of alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, and the like.
[0424] "Alkynyl" refers to an alkyl group having one or more carbon-carbon triple bonds at any position of the chain, which may be monosubstituted or polysubstituted and may be monovalent, divalent or polyvalent. Examples of alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, etc.
[0425] "Cycloalkyl" includes any stable cyclic or polycyclic hydrocarbon radical and any saturated carbon atom, which may be mono- or poly-substituted and may be monovalent, divalent or polyvalent. Examples of such cycloalkyl radicals include, but are not limited to, cyclopropyl, 1, [2.2.2]bicyclooctane, [4.4.0]bicyclononane, etc.
[0426] “Optional” means that the subsequently described event or circumstance may occur but may not occur, and the description includes the existence of the above-mentioned event or circumstance and the non-existence of the event or circumstance described therein.
[0427] "Substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent including deuterium and hydrogen variants, as long as the valence of the particular atom is normal and the substituted compound is stable. When the substituent is a keto group (i.e., =0), it means that two hydrogen atoms are replaced. Keto substitution does not occur on aromatic groups. The term "optionally substituted" means that it may or may not be substituted. Unless otherwise specified, the type and number of substituents can be arbitrary based on what is chemically achievable.
[0428] When any variable (e.g., R) occurs more than one time in any component or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown as substituted with 0 to 2 R, then the group may optionally be substituted with up to two R groups, and R at each occurrence is independently selected from the definition of R. Additionally, combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0429] When the number of bonding groups is zero, such as -(A)0-, the bonding group is a single bond.
[0430] "Alkoxy" refers to an alkyl radical having the specified number of carbon atoms attached via an oxygen bridge. Unless otherwise specified, C 1-6Alkoxy includes C1, C2, C3, C4, C5 and C6 alkoxy. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, t-butoxy, n-pentoxy and S-pentoxy.
[0431] "Aryl" refers to a polyunsaturated aromatic hydrocarbon substituent which may be mono- or poly-substituted and may be monovalent, divalent or polyvalent and may be monocyclic or polycyclic (e.g., 1 to 3 rings; at least one of which is aromatic) which are fused together or linked covalently.
[0432] "Halo" or "halogen" by themselves or as part of another substituent refers to a fluorine, chlorine, bromine, or iodine atom.
[0433] "Haloalkyl" includes both monohaloalkyl and polyhaloalkyl. For example, the term "halo(C 1-4 ")alkyl" includes, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, etc. Unless otherwise specified, examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
[0434] "Heterocycle" refers to a radical of a 3- to 10-membered non-aromatic ring or aromatic ring system having specified ring carbon atoms (e.g., 2 to 6 ring carbon atoms) and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("C 2-6 In heterocyclic groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, where valence permits. A heterocyclic group may be a single ring (a "monocyclic heterocycle") or a fused, bridged or spiro ring system, such as a bicyclic ring system (a "bicyclic heterocycle"), and may be saturated or partially unsaturated. Heterocyclic bicyclic ring systems may include one or more heteroatoms in one or both rings. "Heterocyclic" also includes ring systems in which a heterocycle as defined above is fused to one or more carbocyclic groups, where the point of attachment is on the carbocyclic or heterocyclic ring, or a heterocycle as defined above is fused to one or more aryl or heteroaryl groups, where the point of attachment is on the heterocycle, and in such cases, the number of ring members continues to refer to the number of ring members in the heterocyclic ring system.
[0435] "Nitrogen protecting group" refers to a protecting group used to prevent side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to, formyl; acyl, such as alkanoyl (e.g., acetyl, trichloroacetyl, or trifluoroacetyl); alkoxycarbonyl, such as tert-butyloxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-bis(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like.
[0436] In some embodiments, the heterocyclyl group is a 5-10 membered non-aromatic or aromatic ring system having designated ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclyl group is a 5-6 membered non-aromatic or aromatic ring system having designated ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heterocycle"). In some embodiments, the 5-6 membered heterocycle has 1 to 3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocycle has 1 to 2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocycle has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0437] Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to, azirdinyl, oxirane, and thiorenyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. methyl, morpholinyl, dithianyl and di alkyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, triazacyclohexanyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclic groups containing one heteroatom include, but are not limited to, azocanyl, oxocanyl, and thiocanyl. Exemplary 5-membered heterocyclic groups fused to a C6 aromatic ring (also referred to herein as 5,6-bicyclic heterocycles) include, but are not limited to, indolinyl, isoindolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, benzo Exemplary 6-membered heterocyclic groups fused to an aromatic ring (also referred to herein as 6,6-bicyclic heterocyclic rings) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
[0438] The term "pharmaceutically acceptable salt" means a salt that is harmless to mammals, especially humans. Pharmaceutically acceptable salts can be formed using non-toxic acids or bases, including inorganic acids or inorganic bases, or organic acids or organic bases. Examples of pharmaceutically acceptable salts include metal salts formed with aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, etc., and organic salts formed with lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl reduced glucosamine), procaine, etc. In addition, pharmaceutically acceptable salts contain acid addition salts and base addition salts.
[0439] The term "pharmaceutically acceptable excipient" means a pharmaceutically acceptable material, composition or vehicle, such as saline solution, liquid or solid filler, diluent, solvent or encapsulating agent. Examples of pharmaceutically acceptable excipients include water, saline, saline or phosphate buffered saline (PBS), sodium chloride injection solution, Ringer's injection solution, isotonic dextrose injection solution, sterile water injection solution, dextrose and lactated Ringer's injection solution.
[0440] "Effective amount" means a sufficient amount of a drug or agent to achieve the desired effect without toxicity. For oral formulations of the present invention, an "effective amount" of an active substance in the composition means the amount required to achieve the desired effect when combined with another active substance in the composition. The effective amount varies from individual to individual and depends on the age and general condition of the recipient, as well as the specific active substance.
[0441] The term "solvate" means a solvent-containing compound formed by the combination of one or more solvent molecules with the compound of the present invention. Solvates include, for example, monosolvates, disolvates, trisolvates and tetrasolvates. In addition, solvates include hydrates. The term "hydrate" means a compound that further contains a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces, or a salt thereof. Hydrates include monohydrates, dihydrates, trihydrates, tetrahydrates and the like.
[0442] The term "effective dose" refers to the amount of a compound or composition that will have a targeted effect. For example, in some embodiments, an effective dose may refer to the amount of a compound or composition that will achieve tau imaging.
[0443] The term "tau imaging" means imaging of tau protein accumulated in the brain. This imaging can be performed by positron emission tomography (PET), fluorescence microscopy, multiphoton imaging, two-photon imaging, near-infrared fluorescence imaging, autoradiography, and single-photon emission computed tomography (SPECT).
[0444] The terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease. In some embodiments, treatment is administered after one or more signs or symptoms of a disease have appeared or been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms or a known genetic predisposition). Treatment may also continue after symptoms have resolved, for example to delay or prevent recurrence.
[0445] The compounds of the present invention can be prepared by various synthetic methods known to those skilled in the art, including the embodiments listed below, their combination with other chemical synthetic methods and equivalent alternatives known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present invention.
[0446] Synthesis of compounds:
[0447] The following synthetic procedures are provided as examples and can be used by one of ordinary skill in the art to synthesize the compounds of the present invention.
[0448] Compound of formula (I)
[0449]
[0450] The compounds of general formula (I) are prepared as described in the following scheme:
[0451]
[0452] Compound of formula (II)
[0453]
[0454] The compounds of general formula (II) are prepared as described in the following scheme:
[0455]
[0456] Compound of formula (III)
[0457]
[0458] The compounds of general formula (III) are prepared as described in the following scheme:
[0459]
[0460] Compounds of formula (IV)
[0461]
[0462] The compounds of general formula (IV) are prepared as described in the following scheme:
[0463]
[0464] Compound of formula (V)
[0465]
[0466] The compounds of general formula (V) are prepared as described in the following scheme:
[0467]
[0468] Compound of formula (VI)
[0469]
[0470] The compounds of general formula (VI) are prepared as described in the following scheme:
[0471]
[0472] Other compounds within the scope of the present invention are synthesized by such methods, and by methods similar to those described in the following examples. Additional synthetic methods can be found in WO2019214681, WO2018102067 and WO2019014429, all of which are incorporated herein by reference in their entirety.
[0473] Treatment
[0474] The compounds of the invention are administered to a subject to treat tauopathies, which are disorders or diseases associated with the accumulation of tau aggregates and / or neurofibrillary tangles. Tauopathies include Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), Parkinson's disease (PD), Creutzfeldt-Jakob disease, dementia pugilistica, Down syndrome, Gerstmann-Schönlein disease, British dementia, Danish dementia, inclusion body myositis, prion amyloid cerebrovascular disease, traumatic brain injury, Guam Parkinson's disease-dementia complex syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic granular dementia, corticobasal degeneration, calcifications, and spondylosis. Diffuse neurofibrillary tangles, frontotemporal dementia, frontotemporal dementia with chromosome 17-related parkinsonism, Hall-Strauss disease, multiple system atrophy, Niemann-Pittsburgh disease type C, pallidopomentonigral degeneration, Pick's disease, progressive subcortical gliomatosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, tangle-only dementia, white matter tauopathy with globular glial inclusions, frontotemporal dementia, postencephalitic parkinsonism, chromosome 17-related parkinsonism, and myotonic dystrophy. In some embodiments, the tauopathy is Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick's disease (PiD).
[0475] A.Invest
[0476] After being formulated with appropriate pharmaceutically acceptable excipients at the desired dose, the pharmaceutical compositions of the present invention can be administered to humans and other animals orally, parenterally, intracisternal, intraperitoneal, intrathecal, intracerebroventricular, topically, buccally or the like, depending on the disease or condition to be treated.
[0477] In certain embodiments, the pharmaceutical composition comprising the compounds of the invention is administered orally or parenterally for one or more days at a dosage level sufficient to deliver about 0.001 mg / kg to about 200 mg / kg. In some embodiments, the effective amount of each dose varies within the following range: about 0.001 mg / kg to about 200 mg / kg, about 0.001 mg / kg to about 100 mg / kg, about 0.01 mg / kg to about 100 mg / kg, about 0.01 mg / kg to about 50 mg / kg, about 0.1 mg / kg to about 40 mg / kg, about 0.5 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 10 mg / kg of individual body weight / day, one or more times a day to obtain the desired treatment and / or prevention effect. In some embodiments, the dose of the compounds described herein is sufficient to deliver about 0.001 mg / kg to about 200 mg / kg, about 0.001 mg / kg to about 100 mg / kg, about 0.01 mg / kg to about 100 mg / kg, about 0.01 mg / kg to about 50 mg / kg, about 0.1 mg / kg to about 40 mg / kg, about 0.5 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 10 mg / kg, or about 1 mg / kg to about 25 mg / kg of the subject's body weight / day, one or more times a day, to achieve the desired therapeutic and / or preventive effect. The desired dose can be delivered three times a day, twice a day, once a day, every other day, every three days, every week, every two weeks, every three weeks, or every four weeks. In some embodiments, the dose is delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or more administrations). In some embodiments, the compositions described herein are administered at a dose lower than the dose at which the agent would cause nonspecific effects.
[0478] In some embodiments, at least one additional therapy is administered to the individual. In some embodiments, the additional therapy is a neurological drug, an anti-Tau antibody, a Tau inhibitor, an anti-amyloid β antibody, a β-amyloid aggregation inhibitor, an anti-BACE1 antibody, or a BACE1 inhibitor.
[0479] In some embodiments, the individual is diagnosed as having or being at risk of a Tau-related disease. In some embodiments, the individual is diagnosed as having or being at risk of a tauopathy selected from the group consisting of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick's disease (PiD).
[0480] B. Composition
[0481] The pharmaceutical compositions described herein can be prepared by methods generally known in the art of pharmacology. Generally, such methods include the steps of combining the compounds of the invention with a carrier and / or one or more other additional ingredients, and then shaping and / or packaging the product into a desired single or multiple dosage unit.
[0482] Pharmaceutical compositions can be prepared, packaged and / or sold in bulk, as a single unit dose and / or as a plurality of single unit doses. As used herein, a "unit dose" is an individual amount of a pharmaceutical composition containing a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dose of the active ingredient to be administered to an individual and / or a suitable fraction of such a dose, such as one-half or one-third of such a dose.
[0483] Pharmaceutically acceptable excipients for making pharmaceutical compositions include inert diluents, dispersing and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, stabilizers, buffers, lubricants and / or oils. Excipients such as cocoa butter and suppository waxes, colorants, coatings, sweeteners, flavorings and fragrances may also be present in the composition.
[0484] Suitable diluents include calcium carbonate, sodium carbonate, calcium phosphate, calcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and mixtures thereof.
[0485] Suitable granulating and / or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methyl cellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
[0486] C. Set
[0487] In some embodiments, the kit described herein further includes instructions for use of the kit. The kit described herein may also include information required by regulatory agencies, such as the U.S. Food and Drug Administration (FDA). In some embodiments, the information included in the kit is prescription information. In some embodiments, the kit and instructions are provided for the treatment of diseases (e.g., neurological disorders, neurodegenerative diseases, or tau diseases) of individuals in need. In some embodiments, the kit and instructions are provided for the prevention of diseases (e.g., neurological disorders, neurodegenerative diseases, or tau diseases) of individuals in need. In certain embodiments, the kit and instructions are provided for the reduction of the risk of individuals in need suffering from diseases (e.g., neurological disorders, neurodegenerative diseases, or tau diseases). In some embodiments, the kit and instructions are provided for the promotion of the degradation of tau protein in individuals or cells. In some embodiments, the kit and instructions are provided for the diagnosis of neurological disorders in the central nervous system (e.g., via the use of radiolabeled compounds of the present invention). In some embodiments, the kit and instructions are provided for the imaging and / or detection (e.g., via the use of radiolabeled compounds of the present invention) of neurological disorders in the central nervous system. In some embodiments, kits and instructions are provided for imaging and / or detecting pathological aggregation of tau protein in the central nervous system (e.g., via the use of radiolabeled compounds of the invention).The kits described herein may include one or more additional agents described herein as separate compositions.
[0488] D. Diagnosis
[0489] The compounds of the present invention provide a method for detecting and imaging tau aggregates. This imaging can be performed by molecular imaging methods such as positron emission tomography (PET), fluorescence microscopy, multiphoton imaging, two-photon imaging, near-infrared fluorescence imaging, autoradiography, and single-photon emission computed tomography (SPECT). In addition, this imaging includes in vitro, ex vivo, and in vivo imaging.
[0490] The imaging method comprises administering a radiolabeled compound of the invention to a subject, and detecting said radiolabeled compound of the invention in said subject. The present invention further provides a method of detecting Tau aggregates in vitro or in vivo using a radiolabeled compound of the invention as described herein. Thus, the present invention provides a useful tool for early detection and diagnosis of Alzheimer's disease. The present invention also provides a useful tool for monitoring the progression of Alzheimer's disease and the efficacy of treatment.
[0491] In general, the imaging method may comprise the following steps: (a) administering a radiolabeled compound of the invention to a subject; (b) allowing the radiolabeled compound to bind to Tau in the subject; (c) detecting a signal emitted by the radioisotope in the bound radiolabeled compound; (d) generating an image representing the location and / or amount of the signal; and (e) determining the distribution and extent of Tau aggregates in the subject.
[0492] The step of "administering" the radiolabeled compound of the invention is generally performed parenterally, such as intravenously. The intravenous route represents an effective way to deliver the compound to the entire body of a subject. Intravenous administration presents neither substantial physical intervention nor substantial health risk to the subject. The radiolabeled compound can be administered in the form of a radiopharmaceutical composition. The full definition of the imaging method of the present invention does not require an administration step. Thus, the imaging method of the present invention can also be understood to include steps (b)-(e) defined above performed on a subject to which a radiolabeled compound of the present invention has been previously administered.
[0493] The "detection" step of the method involves detecting the signal emitted by the radioisotope in the radiolabeled compound of the invention by means of a detector sensitive to the signal, such as a PET camera. This detection step can also be understood as the acquisition of signal data.
[0494] The "generating" step of the method of the present invention is performed by a computer that applies a reconstruction algorithm to the acquired signal data to obtain a data set. This data set is then manipulated to generate an image showing the location and / or amount of the signal emitted by the radioisotope. The emitted signal is directly related to the amount of enzyme or neoplastic tissue, so that the "determining" step can be performed by evaluating the generated image.
[0495] The amount of isotopically labeled derivatives and radiolabeled derivatives of the compound for administration one or more times a day to a 70 kg adult may include about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg of the compound per unit dosage form.
[0496] All publications and patent applications mentioned herein are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0497] No admission is made that any reference cited herein constitutes prior art. The discussion of a reference states what its author asserts, and the inventors reserve the right to challenge the accuracy and relevance of the cited document. It should be clearly understood that although various sources of information including scientific journal articles, patent documents, and textbooks are referenced herein; this reference does not constitute an admission that any of these documents form part of the common general knowledge in the art.
[0498] The discussion of the general method given herein is intended for illustrative purposes only. Other alternative methods and alternatives will be apparent to those skilled in the art upon review of the present invention and should be included within the spirit and scope of the present application.
[0499] Examples
[0500] The following examples are provided as further guidance to one of ordinary skill in the art and are not intended to limit the scope of the claimed invention in any way.
[0501] In general, in the following examples, chemicals were purchased from Sinopharm Chemical Reagent Company (SCRC), Sigma-Aldrich, Alfa or other suppliers. Recorded on a Bruker AVIII 400 or Bruker AVIII 500 spectrometer 1 H NMR and 19 F NMR spectroscopy.
[0502] LCMS measurements were performed on an Agilent 1200HPLC / 6100SQ system using the following conditions: Method A: Mobile phase: A: water (0.01% TFA) B: ACN (0.01% TFA); Gradient step: 5% B to 95% B in 1.4 minutes, 95% B for 1.6 minutes (total run time: 3 minutes); Flow rate: 2.3 mL / min; Column: SunFire C18, 4.6×50 mm, 3.5 μm; Column temperature: 50° C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), ES-API. Method B: Mobile phase: A: water (10 mM NH4HCO3) B: acetonitrile; Gradient step: 5% to 95% B in 1.5 minutes, 95% B for 1.5 minutes (total run time: 3 minutes); Flow rate: 2.0 mL / min; Column: XBridge C18, 4.6×50 mm, 3.5 μm; Column temperature: 40°C. Detector: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API). Method C: Mobile phase: A: water (10 mM NH4HCO3) B: acetonitrile; Gradient step: 5% to 95% B in 1.5 minutes, 95% B for 1.5 minutes (total run time: 3 minutes); Flow rate: 2.0 mL / min; Column: XBridge C18, 4.6×50 mm, 3.5 μm; Column temperature: 40°C. Detectors: ADC ELSD, DAD (214nm and 254nm), MSD (ES-API).
[0503] Abbreviations: THF-tetrahydrofuran; DMF-N,N-dimethylformamide; EtOAc-ethyl acetate; DCM-dichloromethane; MeOH-methanol; EtOH-ethanol; TEA-triethanolamine; TFA-trifluoroacetic acid; RT-room temperature.
[0504] Additional embodiments are further disclosed in detail in the following examples, which are provided by way of illustration and are not intended to limit the scope of the invention or the scope of the claims in any way. Although specific alternatives to the invention have been disclosed, it should be understood that various modifications and combinations are possible and are considered within the true spirit and scope of the appended claims. Therefore, it is not intended to be limited to the exact summary and disclosure presented herein.
[0505] Example 1: Synthesis of Compound 159985
[0506]
[0507] (A) 4-methylbenzenesulfonic acid 2-[2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl ester: To a solution of tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (500 mg, 1.12 mmol) in DMF (10 mL) was added NaH (107.49 mg, 4.48 mmol) at 0°C and stirred at room temperature for 1 hour. A solution of 2-[2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (2.65 g, 4.48 mmol) in DMF (10 mL) was added to the reaction mixture and stirred at room temperature for 14 h. The mixture was quenched by adding water at 0 °C and then extracted with EtOAc (200 mL). The organic layer was washed with water (100 mL), brine (100 mL), dried over Na2SO4, concentrated and purified by column chromatography (DCM:MeOH=10:1, Rf=0.7) to give 2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (compound 159835, 603 mg, 0.70 mmol, 62% yield) as a light yellow solid.
[0508] (B) tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate: A mixture of 2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (200 mg, 0.23 mmol) and NaI (42 mg, 0.28 mmol) in CH3CN (5 mL) was heated at 80°C for 20 h. The residue was dissolved in DCM (50 mL) and water (50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2SO4 and concentrated to give tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (compound 159890, 185.1 mg, 0.23 mmol, 98% yield) as a yellow solid.
[0509] (C) N-[2-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamic acid tert-butyl ester: 2-[2,6-bis(oxo)piperidin-3-yl]-5-hydroxy-isoindole-1,3-dimethylamino A mixture of 1-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamic acid tert-butyl ester (100 mg, 0.12 mmol) in DMF (5 mL) was heated at 50° C. for 5 h. The mixture was quenched with water and then extracted with DCM (200 mL). The organic layer was dried over Na2SO4, concentrated, and purified by silica gel column chromatography (DCM:MeOH=20:1, Rf=0.52) to give tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (53 mg, 0.05 mmol, 45% yield) as a light yellow solid.
[0510] (D) 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]isoindole-1,3-dione: N-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]isoindole-1,3-dione To a solution of tert-butyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (52 mg, 0.05 mmol) in DCM (5 mL) was added TFA (0.08 mL, 1.08 mmol) and stirred at room temperature for 20 hours. The mixture was poured into ice water and neutralized to pH 8 with saturated NaHCO3 solution. The residue was dissolved in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4 and concentrated to dryness to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]isoindole-1,3-dione (compound 159985, 41 mg, 0.05 mmol, 83% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6). MS(ESI)m / z867(M+H) + .
[0511] Example 2: Synthesis of Compound 160219
[0512]
[0513] (A) Compound 160087: To a solution of tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (500 mg, 1.12 mmol) in DMF (10 mL) was added NaH (107 mg, 4.48 mmol) at 0°C and stirred at room temperature for 1 hour. A solution of 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (1.86 g, 4.48 mmol) in DMF (10 mL) was added to the reaction mixture and stirred at room temperature for 14 hours. The mixture was cooled to 0°C and quenched with water. The precipitate was collected by filtration, washed with water and purified by column chromatography (DCM:MeOH=20:1, Rf=0.68) to give 2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (595 mg, 0.86 mmol, 77% yield) as a yellow solid.
[0514] (B) Compound 160150: A mixture of 2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (595 mg, 0.86 mmol), NaI (156 mg, 1.04 mmol) in MeCN (15 mL) was heated at 80° C. for 17 hours. The residue was dissolved in DCM (50 mL) and water (50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2SO4 and concentrated to give tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-(2-iodoethoxy)ethyl]carbamate (449 mg, 0.70 mmol, 81% yield) as a yellow solid.
[0515] (C) Compound 160159: A mixture of 2-[2,6-bis(oxo)piperidin-3-yl]-5-hydroxy-isoindole-1,3-dione (96 mg, 0.35 mmol), K2CO3 (96 mg, 0.70 mmol), N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-(2-iodoethoxy)ethyl]carbamic acid tert-butyl ester (150 mg, 0.23 mmol) in DMF (5 mL) was heated at 50° C. for 5 h. Water (10 mL) was added to the mixture and the resulting precipitate was collected by filtration. The residue was purified by column chromatography (DCM:EtOAc=5:2, Rf=0.32) to give tert-butyl N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (121 mg, 0.15 mmol, 66% yield) as a yellow solid.
[0516] (D) Compound 160219: To a solution of tert-butyl N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (120 mg, 0.15 mmol) in DCM (5 mL) was added TFA (0.23 mL, 3.03 mmol), and the mixture was stirred at room temperature for 20 hours. The mixture was poured into ice water and neutralized to pH 8 with saturated NaHCO 3 . The residue was dissolved in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4, and concentrated to dryness to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]isoindole-1,3-dione (21 mg, 0.03 mmol, 18% yield) as a yellow solid.
[0517] Example 3: Synthesis of Compound 160939
[0518]
[0519] (A) Compound 160812: To a solution of tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (500 mg, 1.12 mmol) in DMF (10 mL) was added NaH (107 mg, 4.48 mmol) at 0°C and stirred at room temperature for 1 hour. A solution of 2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (1125 mg, 2.24 mmol) in DMF (5 mL) was added to the reaction mixture and stirred at room temperature for 22 hours. The mixture was dissolved in water (50 mL) and DCM (50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2SO4, concentrated and purified by silica gel column chromatography (EtOAc:DCM=1:5, Rf=0.13) to give 2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (733 mg, 0.94 mmol, 84% yield) as a yellow solid.
[0520] (B) Compound 160829: A mixture of 2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (333 mg, 0.43 mmol) and NaI (109 mg, 0.73 mmol) in CH3CN (10 mL) was heated at 80° C. for 15 h. The solvent was removed by vacuum and the residue was redissolved in EtOAc. The mixture was washed with water (50 mL), brine (50 mL), dried over MgSO4 and concentrated to give tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethyl]carbamate (112 mg, 0.15 mmol, 36% yield) as a yellow solid.
[0521] (C) Compound 160889: A mixture of tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-3a,7a-dihydro-1,3-benzothiazol-6-yl]-N-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethyl]carbamate (112 mg, 0.15 mmol), Cs2CO3 (149.09 mg, 0.46 mmol) and dimethyl 4-hydroxybenzene-1,2-dicarboxylate (64 mg, 0.30 mmol) in DMF (2 mL) was stirred at 50° C. for 1 hour. The mixture was cooled to room temperature and water was added. The precipitate was collected by filtration and then purified by column chromatography (EtOAc:DCM=1:1, Rf=0.33) to give dimethyl 4-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]benzene-1,2-dicarboxylate (102 mg, 0.13 mmol, 82% yield) as a yellow solid.
[0522] (D) Compound 160901: To a solution of dimethyl 4-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]benzene-1,2-dicarboxylate (102 mg, 0.13 mmol) in EtOH (2 mL) was added a solution of NaOH (40 mg, 1 mmol) in water (2 mL). The resulting mixture was stirred at room temperature for 40 hours. The reaction was diluted with EtOAc (10 mL) and acidified to pH 1 with 1 N HCl solution. The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4 and concentrated to dryness to give 4-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]phthalic acid (86 mg, 0.13 mmol, 99.9% yield) as an orange solid.
[0523] (E) Compound 160939: A mixture of 4-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]phthalic acid (122 mg, 0.18 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (32 mg, 0.20 mmol) in pyridine (5 mL) was heated at 120° C. for 19 h. The mixture was cooled to room temperature, diluted with DCM (100 mL) and washed with water (50 mL) and brine (50 mL). The organic layer was collected, dried over Na2SO4, concentrated and purified by column chromatography (MeOH:DCM=1:10, Rf=0.73) to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]isoindole-1,3-dione (49 mg, 0.06 mmol, 35% yield) as a yellow solid.
[0524] Example 4: Synthesis of Compound 161103
[0525]
[0526] (A) Compound 160891: To a solution of tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (500 mg, 1.12 mmol) in DMF (10 mL) was added NaH (107 mg, 4.48 mmol) at 0°C and stirred at room temperature for 1 hour. A solution of 5-(4-methylphenyl)sulfonyloxypentyl 4-methylbenzenesulfonate (1.85 g, 4.48 mmol) in DMF (10 mL) was added to the reaction mixture and stirred at room temperature for 17 hours. The mixture was cooled to 0°C and quenched with water. The resulting precipitate was collected by filtration and purified by column chromatography (DCM:EtOAc=4:1, Rf=0.7) to give 5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyl 4-methylbenzenesulfonate (604 mg, 0.88 mmol, 79% yield) as a yellow solid.
[0527] (B) Compound 160938: A mixture of dimethyl 4-hydroxybenzene-1,2-dicarboxylate (122 mg, 0.58 mmol), Cs2CO3 (285 mg, 0.87 mmol), KI (5 mg, 0.03 mmol) and 5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyl 4-methylbenzenesulfonate (200 mg, 0.29 mmol) in DMF (2 mL) was heated at 50° C. for 2 hours. The reaction was quenched with water. The resulting solid was collected by filtration and washed with water to give dimethyl 4-[5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyloxy]benzene-1,2-dicarboxylate (206 mg, 0.28 mmol, 98% yield) as a yellow solid.
[0528] (C) Compound 160999: To a solution of dimethyl 4-[5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyloxy]benzene-1,2-dicarboxylate (100 mg, 0.14 mmol) in EtOH (2 mL) was added a solution of NaOH (110 mg, 2.76 mmol) in water (2 mL) and stirred at room temperature for 40 hours. The reaction was neutralized to pH 1 with 1 N HCl solution. The precipitate was collected by filtration and washed with water to give 4-[5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyloxy]phthalic acid (93 mg, 0.13 mmol, 97% yield) as a yellow solid.
[0529] (D) Compound 161054: A mixture of 4-[5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyloxy]phthalic acid (93 mg, 0.13 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (48 mg, 0.29 mmol) in pyridine (3 mL) was heated at 120° C. for 40 hours. Water was then added to the mixture. The precipitate was collected by filtration and purified by column chromatography (DCM:EtOAc=4:1, Rf=0.28) to give tert-butyl N-[5-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxypentyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (61 mg, 0.08 mmol, 58% yield) as a yellow solid.
[0530] (E) Compound 161103: To a solution of tert-butyl N-[5-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxypentyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (61 mg, 0.08 mmol) in DCM (5 mL) was added TFA (0.12 mL, 1.55 mmol) and stirred at room temperature for 6 hours. The mixture was poured into ice water and neutralized to pH 8 with saturated NaHCO3 solution. The residue was dissolved in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4, and concentrated to dryness to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]pentyloxy]isoindole-1,3-dione (44 mg, 0.06 mmol, 80% yield) as a yellow solid.
[0531] Example 5: Synthesis of Compound 160273
[0532]
[0533] (A) A mixture of compound 160210: 3-(6-hydroxy-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione (95 mg, 0.37 mmol), K2CO3 (101 mg, 0.73 mmol), tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (200 mg, 0.24 mmol) in DMF (5 mL) was heated at 50° C. for 5 h. The mixture was quenched with water and extracted with DCM (200 mL). The organic layer was collected, dried over Na2SO4, concentrated and purified by column chromatography (DCM:MeOH=20:1, Rf=0.48) to give tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1-oxo-3H-isoindol-5-yl]-oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (83 mg, 0.09 mmol, 36% yield) as a light yellow solid.
[0534] (B) Compound 160273: To a solution of tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (83 mg, 0.09 mmol) in DCM (5 mL) was added TFA (0.13 mL, 1.74 mmol) and stirred at room temperature for 7 hours. The mixture was poured into ice water and neutralized to pH 8 with saturated NaHCO3 solution. The residue was dissolved in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4 and concentrated to dryness to give 3-[6-[2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione (73 mg, 0.08 mmol, 92% yield) as a yellow solid.
[0535] Example 6: Synthesis of Compound 160313
[0536]
[0537] (A) Compound 160284: A mixture of 3-(6-hydroxy-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione (58 mg, 0.22 mmol), K2CO3 (61 mg, 0.44 mmol), tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-(2-iodoethoxy)ethyl]carbamate (95 mg, 0.15 mmol) in DMF (2 mL) was heated at 50° C. for 5 hours. Water (10 mL) was added to the mixture. The resulting precipitate was collected by filtration and then purified by column chromatography (DCM:MeOH=20:1, Rf=0.52) to give tert-butyl N-[2-[2-[[2-[2,6-bis(oxo)piperidin-3-yl]-1-oxo-3H-isoindol-5-yl]oxy]ethoxy]-ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (57 mg, 0.07 mmol, 50% yield) as a yellow solid.
[0538] (B) Compound 160313: To a solution of tert-butyl N-[2-[2-[[2-[2,6-bis(oxo)piperidin-3-yl]-1-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (54 mg, 0.07 mmol) in DCM (5 mL) was added TFA (0.11 mL, 1.39 mmol), and the mixture was stirred at room temperature for 20 hours. The mixture was poured into ice water and neutralized to pH 8 with saturated NaHCO3 solution. The residue was dissolved in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4, and concentrated to dryness to give 3-[6-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione (39 mg, 0.05 mmol, 77% yield) as a yellow solid.
[0539] Example 7: Synthesis of Compound 162640
[0540]
[0541] Compound 162640 was synthesized according to a method similar to that of Example 6.
[0542] 1 H NMR (600MHz, DMSO-d6) δ10.97(s,1H),8.36(s,1H),8.24(d,J=2.3Hz,1H),8.01-8.05(m,4H),7.72(d,J= 8.4Hz,2H),7.62(d,J=8.4Hz,1H),7.52(d,J=9.7Hz,1H),7.17(d,J=1.7Hz,1H),7.05-7.09(m,2H),6.81 -6.85(m,2H),6.61(t,J=5.8Hz,1H),5.07(dd,J=13.2,5.1Hz,1H),4.36(d,J=17.2Hz,1H),4.19-4.27(m ,4H),3.79-3.85(m,7H),3.66(t,J=5.8Hz,3H),3.48-3.54(m,3H),2.85-2.93(m,1H),1.92-1.99(m,1H).
[0543] Example 8: Synthesis of Compound 162842
[0544]
[0545] Compound 162842 was synthesized according to a method similar to Example 6.
[0546] 1H NMR (600MHz, DMSO-d6) δ10.96(s,1H),8.50(d,J=2.5Hz,1H),8.40(s,1H),8.13(d,J=6.6Hz,1H),7.99(d,J=8.2Hz,2H),7.89(dd,J=8 .9,2.5Hz,1H),7.68(d,J=8.2Hz,2H),7.60(d,J=8.4Hz,1H),7.19(s,1H),7.08(d,J=8.4Hz,1H),6.79(t,J=7.4Hz,1H),6.75(d,J=8. 9Hz,1H),6.70(d,J=7.4Hz,1H),5.06(dd,J=13.2,5.1Hz,1H),4.35-4.38(m,2H),4.32(d,J=17.2Hz,1H),4.28(dd,J=8.2,4.5Hz,2H) ,4.20(d,J=17.2Hz,1H),3.96-3.99(m,2H),3.92-3.95(m,2H),3.08(s,7H),2.85-2.93(m,1H),2.26-2.37(m,2H),1.91-1.98(m,2H).
[0547] Example 9: Synthesis of Compound 162903
[0548]
[0549] Compound 162903 was synthesized according to a method similar to Example 6.
[0550] 1 H NMR(600MHz,DMS-d6)δ10.97(s,1H),8.63(d,J=2.4Hz,1H),8.12(s,1H),8.08(d,J=8.0Hz,1H),8.03(dd,J=8 .9,2.6Hz,1H),7.99(d,J=8.9Hz,1H),7.87(d,J=8.0Hz,1H),7.78(d,J=2.4Hz,1H),7.63(d,J=8.4Hz,1H),7.1 8-7.21(m,1H),7.08(dd,J=8.4,2.4Hz,1H),6.79(d,J=8.8Hz,1H),5.08(dd,J=13.4,5.1Hz,1H),4.38(d,J=17 .2Hz,1H),4.22-4.29(m,4H),3.89(dd,J=9.2,5.0Hz,3H),3.11(s,3H),2.56-2.63(m,1H),2.33-2.40(m,1H).
[0551] Example 10: Synthesis of Compound 163123
[0552]
[0553] Compound 163123 was synthesized according to a method similar to that of Example 6.
[0554] 1 H NMR (600MHz, DMSO-d6) δ10.97(s,1H),8.56(d,J=2.5Hz,1H),8.06(d,J=8.4Hz,2H),7.92-7.96(m,2H ),7.82(d,J=8.4Hz,2H),7.74(d,J=2.5Hz,1H),7.62(d,J=8.4Hz,1H),7.13-7.18(m,2H),7.07(dd,J= 8.4,2.1Hz,1H),6.77(d,J=9.0Hz,1H),5.07(dd,J=13.4,5.2Hz,1H),4.35(d,J=17.1Hz,1H),4.22-4 .27(m,6H),3.85-3.91(m,5H),3.10(s,7H),2.85-2.96(m,1H),2.55-2.63(m,2H),2.31-2.42(m,2H).
[0555] Example 11: Synthesis of Compound 163365
[0556]
[0557] Compound 163365 was synthesized according to a method similar to that of Example 6.
[0558] 1H NMR (600MHz, DMSO-d6) δ10.96(s,1H),8.57(d,J=2.5Hz,1H),8.16(d,J=8.4Hz,2H),8.09(s,1H),7.96(dd, J=8.9,2.4Hz,1H),7.86(d,J=8.4Hz,2H),7.68(d,J=8.7Hz,1H),7.62(d,J=8.4Hz,1H),7.45(d,J=2.1Hz,1H ),7.18(s,1H),7.08(d,J=8.3Hz,1H),7.02(dd,J=8.7,2.2Hz,1H),6.77(d,J=8.9Hz,1H),5.07(dd,J=13.3 ,5.2Hz,1H),4.36(d,J=17.2Hz,1H),4.22-4.28(m,5H),3.86-3.91(m,3H),3.10(s,5H),2.84-2.94(m,2H).
[0559] Example 12: Synthesis of Compound 161247
[0560]
[0561] (A) Compound 161084: To a solution of tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (200 mg, 0.45 mmol) in DMF (3 mL) was added NaH (32 mg, 1.34 mmol) at 0°C. The resulting mixture was stirred at room temperature for 1 hour. 2-[2-[2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (454 mg, 0.90 mmol) was added to the reaction mixture and stirred at room temperature for 22 hours. The mixture was quenched with water. The precipitate was collected by filtration and purified by column chromatography (EtOAC:DCM=2:3, Rf=0.48) to give tert-butyl N-[2-[2-[2-[2-[2-[tert-butyl(dimethyl)silanyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (235 mg, 0.30 mmol, 67% yield) as a yellow solid.
[0562] (B) Compound 161112: To a solution of tert-butyl N-[2-[2-[2-[2-[2-[tert-butyl-(dimethyl)silanyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (235 mg, 0.30 mmol) in THF (5 mL) was added dropwise a solution of 1M TBAF in THF (1.81 mL, 1.81 mmol). The reaction mixture was stirred at room temperature for 7 hours. The reaction mixture was concentrated to dryness and the residue was dissolved in EtOAc (100 mL). The mixture was washed with water (100 mL) and brine (100 mL). The organic layer was collected, dried over Na2SO4 and concentrated to give tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-(2-hydroxyethyloxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (200 mg, 0.30 mmol, 99.7% yield) as a yellow solid.
[0563] (C) Compound 161181: To a solution of tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-(2-hydroxyethyloxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (120 mg, 0.18 mmol) in THF (3 mL) was added NaH (9 mg, 0.36 mmol) at 0° C. and stirred for 30 minutes. Then tert-butyl 2-bromoacetate (0.08 mL, 0.54 mmol) was added and the mixture was heated at 50° C. for 8 hours. The solvent was removed by vacuum. The residue was purified by column chromatography (EtOAc:DCM=2:3, Rf=0.35) to give tert-butyl 2-[2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetate (84 mg, 0.11 mmol, 60% yield) as a yellow solid.
[0564] (D) Compound 161218: A mixture of tert-butyl 2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetate (84 mg, 0.11 mmol) and TFA (0.12 mL, 1.61 mmol) in DCM (2 mL) was stirred at room temperature for 23 hours. The mixture was acidified to pH 1 with 1 N HCl solution. The mixture was extracted with DCM. The organic layer was washed with brine, dried over Na2SO4 and concentrated to dryness to give 2-[2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid (60 mg, 0.10 mmol, 89% yield) as a yellow solid.
[0565] (E) Compound 161247: A mixture of (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butyryl]-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide (45 mg, 0.11 mmol), 2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid (60 mg, 0.10 mmol), DIPEA (0.03 mL, 0.14 mmol) and HATU (73 mg, 0.19 mmol) in anhydrous DMF (3 mL) was stirred at room temperature for 18 hours. The mixture was diluted with DCM, washed with water and brine, dried over Na2SO4, concentrated and purified by NH silica gel column chromatography (MeOH:DCM=97:3, Rf=0.48) to give rac-(2R,4S)-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-hydroxy-1-[rac-(2R)-2-[2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetylamino]-3,3-dimethyl-butyryl]pyrrolidine-2-carboxamide (16 mg, 0.01 mmol, 14% yield) as a yellow solid.
[0566] Example 13: Synthesis of Compound 160275
[0567]
[0568] (A) Compound 160161: To a solution of NaH (81 mg, 2.02 mmol) in DMF (1 mL) was added a solution of tert-butyl N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (300 mg, 0.67 mmol) in DMF (6 mL) at 0° C. and stirred at 25° C. for 30 min. A solution of 2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (794 mg, 1.34 mmol) in DMF (3 mL) was added to the reaction mixture and heated at 50° C. for 2 h. The mixture was quenched with saturated NH4Cl solution and extracted with DCM. The organic layer was washed with brine, dried over MgSO4, concentrated and purified by column chromatography (MeOH:DCM=3:97, Rf=0.3) to give 2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (273 mg, 0.32 mmol, 47% yield) as a yellow oil.
[0569] (B) Compound 160244: A mixture of 2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (270 mg, 0.31 mmol) and NaI (56.18 mg, 0.37 mmol) in CH3CN (5 mL) was heated at 80°C for 19 hours. The mixture was diluted with DCM and extracted with water (50 mL) and brine (50 mL). The organic layer was dried over MgSO4 and concentrated to dryness to give tert-butyl N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (256 mg, 0.31 mmol, 99.9% yield) as an orange oil.
[0570] (C) Compound 160252: A mixture of 2-[2,6-bis(oxo)piperidin-3-yl]-5-hydroxy-isoindole-1,3-dione (102 mg, 0.37 mmol), K2CO3 (77 mg, 0.56 mmol) and tert-butyl N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (153 mg, 0.19 mmol) in DMF (4 mL) was heated at 50° C. for 18 h. The mixture was diluted with DCM (200 mL) and extracted with water. The organic layer was collected, dried over MgSO4, concentrated and purified by column chromatography (MeOH:DCM=5:95, Rf=0.3) to give tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (61 mg, 0.06 mmol, 34% yield) as a yellow solid.
[0571] (D) Compound 160275: To a solution of tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (61 mg, 0.06 mmol) in DCM (1 mL) was added TFA (0.5 mL, 6.53 mmol) at 0°C. The resulting mixture was stirred at room temperature for 5 hours. The solution was neutralized with saturated NaHCO3 solution at 0°C and extracted with DCM. The organic layer was washed with brine, dried over MgSO4, concentrated and purified by NH silica gel column chromatography (MeOH:DCM=99:1, Rf=0.3) to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]isoindole-1,3-dione (51 mg, 0.05 mmol, 86% yield) as a yellow solid.
[0572] Example 14: Synthesis of Compound 161177
[0573]
[0574] (A) Compound 161026: A mixture of dimethyl 4-hydroxyphthalate (139 mg, 0.62 mmol), Cs2CO3 (303 mg, 0.93 mmol), tert-butyl N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-(2-iodoethoxy)ethyl]carbamate (200 mg, 0.31 mmol) in DMF (5 mL) was heated at 50° C. for 1 hour. The mixture was quenched with water and extracted with DCM. The organic layer was dried over MgSO4, concentrated and purified by column chromatography (EtOAc:Hex=1:1, Rf=0.4) to give dimethyl 4-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]benzene-1,2-dicarboxylate (148 mg, 0.20 mmol, 66% yield) as a yellow solid.
[0575] (B) Compound 161083: To a solution of dimethyl 4-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]benzene-1,2-dicarboxylate (148 mg, 0.20 mmol) in MeOH (1 mL) and water (1 mL) was added LiOH (39 mg, 1.63 mmol). The reaction mixture was stirred at room temperature for 5 days. The solution was acidified to pH 4 to 5 with 1N HCl. The resulting precipitate was collected by filtration, washed with water and dried under vacuum to give 4-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]phthalic acid (119 mg, 0.17 mmol, 84% yield) as a yellow solid.
[0576] (C) Compound 161115: A mixture of 4-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]phthalic acid (119 mg, 0.17 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (31 mg, 0.19 mmol) in pyridine (2 mL) was heated at 120° C. for 2 days. The mixture was concentrated to dryness and purified by column chromatography (MeOH:DCM=5:95, Rf=0.3) to give tert-butyl N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (39 mg, 0.05 mmol, 29% yield) as a yellow solid.
[0577] (D) Compound 161177: To a solution of tert-butyl N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (39 mg, 0.05 mmol) in DCM (1 mL) was added TFA (1 mL, 13.06 mmol) at 0°C. The resulting mixture was stirred at room temperature for 2 hours. The solution was neutralized with saturated NaHCO3 solution and extracted with DCM. The organic layer was washed with brine, dried over MgSO4, concentrated and purified by chromatography (MeOH:DCM=1:99, Rf=0.1) to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]isoindole-1,3-dione (11 mg, 0.02 mmol, 31% yield) as a yellow solid.
[0578] Example 15: Synthesis of Compound 160383
[0579]
[0580] (A) Compound 160366: A mixture of 3-(6-hydroxy-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione (63 mg, 0.24 mmol), K2CO3 (51 mg, 0.37 mmol), N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamic acid tert-butyl ester (100 mg, 0.12 mmol) in DMF (2 mL) was heated at 50°C for 3 hours. The mixture was quenched with water, extracted with DCM (200 mL), dried over MgSO4, concentrated and purified by chromatography (MeOH:DCM=5:95, Rf=0.3) to give tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (26 mg, 0.03 mmol, 22% yield) as a yellow solid.
[0581] (B) Compound 160383: To a solution of tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (26 mg, 0.03 mmol) in DCM (1 mL) was added TFA (0.5 mL, 6.53 mmol) at 0° C., and the mixture was stirred at room temperature for 3 hours. The solution was neutralized with saturated NaHCO 3 solution at 0° C. and then extracted with DCM. The organic layer was washed with brine, dried over MgSO4, concentrated and purified by chromatography (MeOH:DCM=5:95, Rf=0.2) to give 3-[6-[2-[2-[2-[2-[2-[2-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione (9 mg, 0.01 mmol, 33% yield) as a yellow solid.
[0582] Example 16: Synthesis of Compound 160744
[0583]
[0584] (A) Compound 160690: To a solution of 2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-ol (400 mg, 1.15 mmol) in DMF (10 mL) was added NaH (184 mg, 4.59 mmol) at 0°C and stirred at room temperature for 1 hour. 4-Methylbenzenesulfonic acid 2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl ester (2 mL, 4.13 mmol) was added to the mixture and stirred at room temperature for 14 hours under argon. The mixture was diluted with DCM (10 mL), washed with water (10 mL) and brine (10 mL). The organic layer was collected, dried over Na2SO4, concentrated and purified by column chromatography (DCM:MeOH=50:1, Rf=0.29) to give 2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (520 mg, 0.68 mmol, 59% yield) as a light yellow solid.
[0585] (B) Compound 160707: A mixture of 2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (520 mg, 0.68 mmol) and NaI (122 mg, 0.81 mmol) in CH3CN (6 mL) was heated at 80° C. for 5 h. To the mixture was added water and extracted with DCM. The organic layer was washed with water (20 mL), brine (20 mL), dried over Na2SO4, concentrated and purified by chromatography (MeOH:DCM=1:50, Rf=0.39) to give 6-fluoro-5-[4-[6-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]imidazo[1,2-a]pyridin-2-yl]phenyl]-N,N-dimethyl-pyridin-2-amine (427 mg, 0.59 mmol, 87% yield) as a light yellow solid.
[0586] (C) Compound 160744: A mixture of 2-[2,6-bis(oxo)piperidin-3-yl]-5-hydroxy-isoindole-1,3-dione (114 mg, 0.41 mmol), Cs2CO3 (202 mg, 0.62 mmol) and 6-fluoro-5-[4-[6-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3,8a-dihydroimidazo[1,2-a]pyridin-2-yl]phenyl]-N,N-dimethyl-pyridin-2-amine (150 mg, 0.21 mmol) in DMF (3 mL) was heated at 50° C. for 20 h. The mixture was quenched with water and the resulting precipitate was collected by filtration. The residue was purified by column chromatography (MeOH:DCM=1:20, Rf=0.34) to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]isoindole-1,3-dione (28 mg, 0.03 mmol, 15% yield) as a brown solid.
[0587] 1 H NMR (400MHz, DMSO-d6) δ11.09(s,1H),8.28(s,1H),8.23(d,J=2.3Hz,1H),7.97(d,J=7.8,2H),7.87(dd,J=10. 8,8.4Hz,1H),7.81(d,J=8.4Hz,1H),7.57(d,J=7.8Hz,2H),7.50(d,J=9.7Hz,1H),7.43(d,J=2.3Hz,1H),7.34 (dd,J=8.4,2.3Hz,1H),7.05(dd,J=9.7,2.3Hz,1H),6.63(dd,J=8.4,2.0Hz,1H),5.11(dd,J=12.9,5.5Hz,1H) ,4.25-4.32(m,2H),4.06-4.14(m,2H),3.74-3.79(m,4H),3.47-3.63(m,18H),3.06(s,6H),2.80-2.96(m,2H).
[0588] Example 17: Synthesis of Compound 161111
[0589]
[0590] (A) Compound 160947: To a solution of 2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-ol (400 mg, 1.15 mmol) in anhydrous DMF (8 mL) was added NaH (0.14 g, 3.44 mmol) at 0°C and stirred at room temperature for 1 hour. 4-Methylbenzenesulfonic acid 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl ester (1.43 g, 3.44 mmol) was added to the mixture and stirred at the same temperature for 16 hours. The reaction was quenched with water and extracted with DCM. The organic layer was washed with water and brine, dried over Na2SO4, concentrated and purified by silica gel column chromatography (EtOAc:DCM=1:5, Rf=0.33) to give 4-methylbenzenesulfonic acid 2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethyl ester (227 mg, 0.38 mmol, 33% yield) as an orange solid.
[0591] (B) Compound 160997: A mixture of dimethyl 4-hydroxybenzene-1,2-dicarboxylate (161 mg, 0.77 mmol), Cs2CO3 (374.2 mg, 1.15 mmol), KI (6 mg, 0.04 mmol) and 2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethyl 4-methylbenzenesulfonate (226 mg, 0.38 mmol) in DMF (4 mL) was heated at 50°C for 4 hours. The mixture was quenched with water and the resulting precipitate was collected by filtration and washed with water to give dimethyl 4-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethoxy]benzene-1,2-dicarboxylate (212 mg, 0.34 mmol, 88% yield) as an orange solid.
[0592] (C) Compound 161006: To a solution of dimethyl 4-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethoxy]benzene-1,2-dicarboxylate (211 mg, 0.34 mmol) in MeOH (2 mL) was added a solution of NaOH (443 mg, 11.08 mmol) in water (2 mL) and stirred at room temperature for 5 days. The reaction was diluted with EtOAc (50 mL) and acidified to pH 1 with 1 N HCl solution. The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2SO4 and concentrated to give 4-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethoxy]phthalic acid (185 mg, 0.31 mmol, 92% yield) as a yellow solid.
[0593] (D) Compound 161111: A mixture of 4-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethoxy]phthalic acid (67 mg, 0.11 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (20 mg, 0.15 mmol) in pyridine (3 mL) was heated at 120° C. for 14 hours. The solvent was removed by vacuum. The residue was redissolved in DCM and water was added. The resulting precipitate was collected by filtration and purified by column chromatography (MeOH:DCM=1:100, Rf=0.19) to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]oxyethoxy]ethoxy]isoindole-1,3-dione (18 mg, 0.02 mmol, 22% yield) as a yellow solid.
[0594] Example 18: Synthesis of Compound 161215
[0595]
[0596] (A) Compound 160806: To a solution of NaH (138 mg, 3.45 mmol) in DMF (2 mL) was added a solution of tert-butyl N-[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (500 mg, 1.15 mmol) in DMF (10 mL) at 0°C. The resulting mixture was stirred at room temperature for 30 minutes. A solution of 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (954 mg, 2.30 mmol) in DMF (3 mL) was added to the reaction mixture and stirred at room temperature for 21 hours. The mixture was quenched with saturated NH4Cl solution and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4, concentrated and purified by column chromatography (EtOAc:DCM=3:17, Rf=0.3) to give 2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (339 mg, 0.50 mmol, 44% yield) as a yellow solid.
[0597] (B) Compound 160814: A mixture of 2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (339 mg, 0.50 mmol) and NaI (90 mg, 0.60 mmol) in MeCN (10 mL) was heated at 80° C. for 19 h. The mixture was added to water and extracted with EtOAc. The organic layer was washed with water (50 mL), brine (50 mL), dried over MgSO4, concentrated, and purified by column chromatography (EtOAc:DCM=1:9, Rf=0.3) to give tert-butyl N-[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-N-[2-(2-iodoethoxy)ethyl]carbamate (197 mg, 0.31 mmol, 62% yield) as a yellow solid.
[0598] (C) Compound 161091: A mixture of dimethyl 4-oxobenzene-1,2-dicarboxylate (131 mg, 0.62 mmol), Cs2CO3 (305 mg, 0.93 mmol), N-[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-N-[2-(2-iodoethoxy)ethyl]carbamic acid tert-butyl ester (197 mg, 0.31 mmol) in DMF (5 mL) was heated at 50°C for 1 hour. The mixture was quenched with water, extracted with DCM, dried over MgSO4, concentrated, and purified by column chromatography (EtOAc:hexane=1:1, Rf=0.3) to give dimethyl 4-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]benzene-1,2-dicarboxylate (147 mg, 0.21 mmol, 66% yield) as a yellow solid.
[0599] (D) Compound 161105: To a solution of dimethyl 4-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]benzene-1,2-dicarboxylate (147 mg, 0.21 mmol) in MeOH (2 mL) was added a solution of NaOH (66 mg, 1.65 mmol) in water (2 mL), and the mixture was stirred at room temperature for 3 days. The reaction was neutralized to pH 1 with 1N HCl solution. The precipitate was collected by filtration and washed with water to give 4-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]phthalic acid (135 mg, 0.20 mmol, 96% yield) as a white solid.
[0600] (E) Compound 161183: A mixture of 4-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]phthalic acid (135 mg, 0.20 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (49 mg, 0.29 mmol) in pyridine (2 mL) was heated at 120° C. for 20 hours. The mixture was concentrated to dryness and purified by NH silica gel column chromatography (MeOH:DCM=1:99, Rf=0.1) to give tert-butyl N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (47 mg, 0.06 mmol, 30% yield) as a yellow solid.
[0601] (F) Compound 161215: To a solution of tert-butyl N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (47 mg, 0.06 mmol) in DCM (1 mL) was added TFA (1 mL, 13 mmol) at 0° C. and the mixture was stirred at room temperature for 2 hours. The solution was neutralized with saturated NaHCO 3 solution and extracted with DCM. The organic layer was washed with brine, dried over MgSO4, concentrated and purified by NH silica gel chromatography (MeOH:DCM=1:99, Rf=0.1) to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]isoindole-1,3-dione (17 mg, 0.02 mmol, 38% yield) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.28(s,1H),8.19(d,J=2.3Hz,1H),7.92(d,J=8.3Hz,2H),7.79(d,J=8. 3Hz,1H),7.70(dd,J=10.3,8.2Hz,1H),7.46-7.52(m,3H),7.43(d,J=2.2Hz,1H),7.34(dd,J=8.2,2.3Hz,1H),7 .14(t,J=5.7Hz,1H),7.01(dd,J=10.3,2.2Hz,1H),6.49(d,J=8.5Hz,1H),5.08(dd,J=13.1,5.3Hz,1H),4.34- 4.28(m,2H),3.75-3.83(m,5H),3.62(t,J=5.5Hz,2H),3.39-3.44(m,2H),2.77-2.91(m,1H),2.49-2.66(m,2).
[0602] Example 19: Synthesis of Compound 161409
[0603]
[0604] Compound 161409 can be synthesized by a method similar to Example 19.
[0605] 1 H NMR (400MHz, DMSO-d6) δ11.09(s,1H),8.27(s,1H),8.19(d,J=2.5Hz,1H),7.92(d,J=8.0Hz,2H),7.78(d,J= 8.4Hz,1H),7.71(dd,J=10.2,8.6Hz,1H),7.45-7.53(m,3H),7.41(d,J=2.0Hz,1H),7.32(dd,J=8.6,2.1Hz,1 H),7.13(t,J=5.3Hz,1H),7.00(dd,J=9.7,1.6Hz,1H),6.49(d,J=9.2Hz,1H),5.07(dd,J=12.8,5.3Hz,1H),4 .24-4.29(m,2H),3.77(s,3H),3.72-3.76(m,2H),3.44-3.58(m,20H),3.34-3.41(m,3H),2.77-2.91(m,2H).
[0606] Example 20: Synthesis of Compound 161104
[0607]
[0608] (A) Compound 160937: To a solution of tert-butyl 2-[4-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]-pyridine-1-carboxylate (500 mg, 1.03 mmol) in DMF (10 mL) was added NaH (49 mg, 1.23 mmol) at 0°C and stirred at room temperature for 30 minutes. 2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (789 mg, 1.34 mmol) was added to the reaction mixture and stirred at room temperature for 6 hours. The mixture was quenched with saturated NH4Cl solution and extracted with DCM. The organic layer was washed with brine, dried over MgSO4, concentrated and purified by column chromatography (EtOAc:DCM=1:4, Rf=0.33) to give 2-[4-[6-[2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (280 mg, 0.31 mmol, 30% yield) as a light yellow oil.
[0609] (B) Compound 160987: A solution of dimethyl 4-hydroxybenzene-1,2-dicarboxylate (130.05 mg, 0.62 mmol), Cs2CO3 (303 mg, 0.93 mmol) and 2-[4-[6-[2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-1-carboxylate tert-butyl ester (280 mg, 0.31 mmol) in DMF (3 mL) was heated at 50° C. for 3 h. The mixture was quenched with water and the resulting precipitate was collected by filtration. The solid was then purified by column chromatography (EtOAc:DCM=4:1, Rf=0.32) to give dimethyl 4-[2-[2-[2-[2-[2-[2-[(2-methylpropan-2-yl)oxycarbonyl-[5-[4-[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]benzene-1,2-dicarboxylate (98 mg, 0.10 mmol, 34% yield) as a light yellow oil.
[0610] (C) Compound 161004: To a solution of dimethyl 4-[2-[2-[2-[2-[2-[2-[(2-methylpropan-2-yl)oxycarbonyl-[5-[4-[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]benzene-1,2-dicarboxylate (98 mg, 0.10 mmol) in EtOH (5 mL) was added a solution of NaOH (33 mg, 0.83 mmol) in water (5 mL) and stirred at room temperature for 4 days. The reaction was diluted with DCM (10 mL) and acidified to pH 1 with 1 N HCl solution. The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4 and concentrated to dryness to give 4-[2-[2-[2-[2-[2-[2-[2-[5-[4-[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]phthalic acid (79 mg, 0.10 mmol, 93% yield) as a light yellow solid.
[0611] (D) Compound 161045: A mixture of 4-[2-[2-[2-[2-[2-[2-[2-[5-[4-[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]phthalic acid (79 mg, 0.10 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (18 mg, 0.11 mmol) in pyridine (3 mL) was heated at 120° C. for 42 hours. The solvent was removed in vacuo. The residue was redissolved in DCM (10 mL), washed with brine, dried over Na2SO4, concentrated and purified by column chromatography (MeOH:DCM=1:19, Rf=0.3) to give tert-butyl 2-[4-[6-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-1-carboxylate (22 mg, 0.02 mmol, 25% yield) as a yellow solid.
[0612] (E) Compound 161104: To a solution of tert-butyl 2-[4-[6-[2-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-1,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-1-carboxylate (22 mg, 0.02 mmol) in DCM (3 mL) was added TFA (0.03 mL, 0.36 mmol), and the mixture was stirred at room temperature for 42 hours. The mixture was neutralized to pH 8 with saturated NaHCO3 and extracted with DCM (10 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated to dryness to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[2-[5-[4-(1H-pyrrolo[2,3-c]pyridin-2-yl)phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]isoindole-1,3-dione (15 mg, 0.02 mmol, 73% yield) as a yellow solid.
[0613] Example 21: Synthesis of Compound 160624
[0614]
[0615] Compound 160557: A mixture of 3-(6-oxoalkyl-3-oxyalkylene-1H-isoindol-2-yl)piperidine-2,6-dione (169 mg, 0.65 mmol), Cs2CO3 (317 mg, 0.97 mmol), N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-(2-iodoalkylethoxy)ethyl]carbamic acid tert-butyl ester (209 mg, 0.32 mmol) in DMF (5 mL) was heated at 50°C for 1 hour. The mixture was quenched with water, extracted with DCM, dried over MgSO4, concentrated and purified by column chromatography (solvent gradient 0% to 3% MeOH / DCM, Rf = 0.2) to give tert-butyl (5-(4-(6-(dimethylamino)benzo[d]thiazol-2-yl)phenyl)pyridin-2-yl)(2-(2-(3-(5-hydroxy-1-oxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)ethoxy)ethyl)carbamate (68 mg, 0.09 mmol, 27% yield) as a yellow solid.
[0616] Compound 160624: To a solution of tert-butyl (5-(4-(6-(dimethylamino)benzo[d]thiazol-2-yl)phenyl)pyridin-2-yl)(2-(2-(3-(5-hydroxy-1-oxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)ethoxy)ethyl)carbamate (68 mg, 0.09 mmol) in DCM (2 mL) was added TFA (1 mL, 13.06 mmol) at 0° C. and stirred at room temperature for 6 hours. The solution was neutralized with saturated NaHCO 3 solution at 0° C. and extracted with DCM. The organic layer was washed with brine, dried over MgSO4 and concentrated to dryness to give 1-(2-(2-((5-(4-(6-(dimethylamino)benzo[d]thiazol-2-yl)phenyl)pyridin-2-yl)amino)ethoxy)ethyl)-3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione (51 mg, 0.07 mmol, 85% yield) as a yellow solid.
[0617] Example 22: Synthesis of Compound 162641
[0618]
[0619] Compound 162586: To a solution of tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]-N-[2-(2-iodoalkylethoxy)ethyl]carbamate (100 mg, 0.16 mmol) in DMF (5 mL) was added 3-(7-azanyl-3-oxyalkylidene-1H-isoindol-2-yl)piperidine-2,6-dione (48 mg, 0.19 mmol) and K2CO3 (101 mg, 0.31 mmol) and heated at 80°C for 3 h. The mixture was diluted with DCM, washed with water and brine, dried over Na2SO4, concentrated and purified by column chromatography (MeOH:DCM=1:20, Rf=0.3) to give tert-butyl N-[2-[2-[3-(7-azanyl-3-oxyalkylidene-1H-isoindol-2-yl)-2,6-bis(oxyalkylidene)piperidin-1-yl]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (70 mg, 0.09 mmol, 58% yield) as a yellow solid.
[0620] Compound 162641: To a solution of tert-butyl N-[2-[2-[3-(7-azanyl-3-oxyalkylene-1H-isoindol-2-yl)-2,6-bis(oxyalkylene)piperidin-1-yl]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]carbamate (70 mg, 0.09 mmol) in DCM (2 mL) was added TFA (0.1 mL, 1.35 mmol) and stirred at room temperature for 20 hours. The mixture was neutralized to pH 8 with saturated NaHCO3 solution. The residue was dissolved in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL) and brine (10 mL), dried over Na2SO4 and concentrated to give 3-(7-azanyl-3-oxyalkylidene-1H-isoindol-2-yl)-1-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-1,3-benzothiazol-6-yl]amino]ethoxy]ethyl]piperidine-2,6-dione (30 mg, 0.04 mmol, 46% yield) as a yellow solid.
[0621] Example 23: Synthesis of Compound 161598
[0622]
[0623] Compound 161444: To a solution of tert-butyl N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (200 mg, 0.45 mmol) in DMF (5 mL) was added NaH (43 mg, 1.79 mmol) at 0°C and stirred at room temperature for 1 hour. 2-[2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (681 mg, 1.34 mmol) was added to the mixture and stirred at the same temperature for 24 hours. The reaction was quenched by adding water. The obtained solid was collected by filtration and purified by column chromatography (EtOAc:DCM=7:3, Rf=0.4) to give tert-butyl N-[2-[2-[2-[2-[2-[tert-butyl(dimethyl)silanyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (252 mg, 0.32 mmol, 72% yield) as a yellow oil.
[0624] Compound 161467: To a solution of tert-butyl N-[2-[2-[2-[2-[2-[tert-butyl(dimethyl)silanyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (252 mg, 0.32 mmol) in THF (5 mL) was added TBAF (1 M THF solution, 1.94 mL, 1.94 mmol) dropwise and stirred at room temperature for 19 hours. The reaction mixture was concentrated to dryness and the residue was dissolved in EtOAc (50 mL). The mixture was washed with water (50 mL) and brine (50 mL), dried over Na2SO4. The reaction mixture was concentrated to dryness to give tert-butyl N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-(2-hydroxyethyloxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (214 mg, 0.32 mmol, 99% yield) as a yellow oil.
[0625] Compound 161530: To a mixture of tert-butyl N-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-(2-hydroxyethyloxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (214 mg, 0.32 mmol) and tert-butyl 2-bromohydroacetate (0.14 mL, 0.96 mmol) in THF (3 mL) was added NaH (19 mg, 0.80 mmol) at 0° C. and stirred at room temperature for 42 hours. The reaction was quenched by the addition of water. The mixture was diluted with DCM (50 mL), washed with water (50 mL) and brine (50 mL), dried over Na2SO4, concentrated to dryness and purified by column chromatography (EtOAc:Hex=1:1, Rf=0.35) to give tert-butyl 2-[2-[2-[2-[2-[2-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetate (130 mg, 0.17 mmol, 52% yield) as a yellow oil.
[0626] Compound 161586: To a solution of tert-butyl 2-[2-[2-[2-[2-[2-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetate (130 mg, 0.17 mmol) in DCM (2 mL) was added TFA (0.38 mL, 4.99 mmol) and stirred at room temperature for 22 h. The mixture was concentrated to dryness to give 2-[2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid TFA salt (179 mg, 0.29 mmol, >99% yield) as an orange oil.
[0627] Compound 161598: A mixture of (2S,4R)-1-[(2S)-2-azanyl-3,3-dimethyl-butyryl]-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxoalkyl-pyrrolidine-2-carboxamide (79 mg, 0.18 mmol), 2-[2-[2-[2-[2-[2-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid (104 mg, 0.17 mmol), DIPEA (0.04 mL, 0.25 mmol) and HATU (127 mg, 0.33 mmol) in anhydrous DMF (3 mL) was stirred at room temperature for 18 hours. The mixture was dissolved in DCM, washed with water and brine, dried over anhydrous Na2SO4, concentrated and purified by column chromatography (MeOH:DCM=3:100, Rf=0.32) to give rac-(2R,4S)-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxoalkyl-1-[rac-(2R)-2-[2-[2-[2-[2-[2-[2-[5-[4-[6-(dimethylamino)-1,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetylamino]-3,3-dimethyl-butyryl]pyrrolidine-2-carboxamide (16 mg, 0.01 mmol, 8% yield) as a yellow solid.
[0628] Example 24: In vitro fluorescence-based recombinant tau binding assay
[0629] (A) Expression and purification of human tau: 1 mM IPTG (Sangon Biotech, catalog number A100487) was used to induce tau production in bacteria (BL21, Invitrogen, catalog number C600003) transformed with full-length 2N4R tau expression plasmids. After 3 hours, cell pellets were resuspended in lysis buffer (100 mM PIPES, 1 mM EGTA, 1 mM MgSO4, pH 6.8) and lysed by sonication, followed by centrifugation (15,000 rpm, 15 min, 4°C). The supernatant was then placed in a boiling water bath for 20 min, followed by centrifugation (15,000 rpm, 15 min, 4°C). The supernatant was loaded onto a Q-100 plate. The flow-through fraction was loaded onto a Fast Flow column (GE healthcare, catalog number 17-0510-01). Fast Flow column (GE healthcare, catalog number 17-0729-01), and tau protein was eluted with elution buffer (100 mM PIPES, 1 M NaCl, 1 mM EGTA, 1 mM MgSO4, 0.2 M NaCl, pH 6.8). The collected tau-containing fractions were pooled, concentrated and dialyzed against HEPES buffer (25 mM HEPES, 0.1 mM EDTA, 0.5 mM DTT, 100 mM NaCl, pH 7.2) and stored in small aliquots at -80°C until use. Protein concentration was determined by UV absorption.
[0630] (B) Preparation of heparin-induced aggregated tau (aTau): 2 μM tau prepared in 30 mM Tris-HCl pH 7.5 buffer was incubated with 15 μM heparin (Sigma, catalog number H3149) in a tube at 37° C. for 24 hours.
[0631] (C) Compound fluorescence spectroscopy scanning analysis: Compounds were dissolved in 100% DMSO, and 40 nM aTau was incubated with 10 μM of each compound in 2% DMSO in a 96-well plate (Corning, catalog number 3573) at 37° C. for 1 hour. The emission and excitation of the compounds were scanned by a microplate spectrometer (EnSpire 2300, PerkinElmer).
[0632] (D) In vitro fluorescent aTau binding assay: 2 μM aTau was diluted to 0.04 μM with 30 mM Tris-HCl (pH 6.8), and then incubated with serially diluted compounds (three-fold serial dilution, 10 to 0.00017 μM) in a 96-well plate (Corning, catalog number 3573) at 37°C for 1 hour. The fluorescence intensity of APN-0729 (excitation / emission = 370 / 500 nm) was read by a microplate spectrometer (EnSpire 2300, PerkinElmer). Compound Kd values were calculated using the following equation: Y = B max ×X / (Kd+X), where X is the concentration of the compound; Y is the fluorescence signal of (compound+aTau)-(compound+DMSO); and B max The results are shown in Table 2 below.
[0633] Table 2: Competition analysis with PBB5
[0634] Compound Ex / Em(nm) Kd(μM) PBB5 (μM) Bmax(%) 159985 375 / 485 0.10 0.32 71 160219 375 / 480 0.11 0.15 69 160273 375 / 495 0.47 0.27 59 160313 370 / 500 0.08 0.22 64 160275 375 / 505 0.23 1.29 96 160703 390 / 500 0.10 1.00 =100 160383 375 / 525 0.55 0.27 80 160624 380 / 500 0.12 0.55 =100 160744 355 / 405 0.15 5.96 113 160570 350 / 520 0.36 2.26 =100 160371 300 / 400 0.29 >10 =100.0
[0635] (E) PBB5 competition assay: 2 μM aTau was diluted to 0.12 μM with mM Tris-HCl (pH 6.8) and then incubated with 0.1 μM 2-(4-(2-(methylamino)pyridin-5-yl)-1,3-butadien-1-yl)benzothiazol-6-ol (PBB5) and serially diluted compounds (three-fold serial dilution, 10 to 0.00017 μM) in a 96-well plate (Corning, catalog number 3573) at 37° C. for 1 hour. The fluorescence intensity of PBB5 (excitation / emission=530 / 690 nm) was read by a microplate spectrometer (EnSpire2300, PerkinElmer). The competition percentage was calculated using the following equation: (Max - compound only wells) / (Max - Min) x 100%, where Max = (Tau + PBB5) signal - (buffer + PBB5) signal; and Min = (buffer + PBB5) signal - (buffer + PBB5) signal.
[0636] IC of each compound 50 Values were calculated using GraphPad Prism software using a 4-parameter logistic model or a sigmoidal dose-response model:
[0637] Y = Bottom + (Top - Bottom) / (1 + (IC50 / X)^HillSlope)
[0638] To test the tau binding ability of the compounds, a fluorescence-based in vitro tau binding assay was performed. All compounds retained tau binding ability and competitive properties with PBB5.
[0639] Example 25: Cell-based Tau binding assay
[0640] (A) Preparation of mouse brain lysate as a source of tau seeds: Three-month-old WT and rTg4510 mice were sacrificed by cervical dislocation. The brain was quickly removed from the skull, weighed, the cerebellum discarded, and the remaining brain was dissected along the midline on ice. Half of each brain was placed in a homogenization tube (MP Biomedicals) and kept on ice. 5 volumes of ice-cold homogenization buffer were added relative to the weight of the brain. The homogenate was vortexed at 6 m / s for 40 seconds by FastPrep-24TM 5G (MP biomedicals), and then centrifuged (Eppendorf) at 13,000×g at 4°C for 15 minutes. The supernatant of the brain lysate was transferred to a new microcentrifuge tube and stored at -80°C.
[0641] Because the homogenization buffer is slightly toxic to HEK cells, the brain lysate undergoes a buffer exchange from a Tris-based buffer to PBS. The brain lysate is thawed on ice. Sterile PBS is added to a 2 ml centrifugal filter tube (10K cutoff, Amicon), and then centrifuged at 4500 × g for 2 minutes at 4 ° C to rinse the tube. The thawed lysate is added to the filter tube and filled to 2 mL with 1 × sterile PBS. The tube is centrifuged at 4500 × g for 60 minutes at 4 ° C. Repeat the PBS washing step. After the centrifugation step, 300 μL of supernatant in the bottom of the centrifuge tube is collected and kept on ice. Repeat the remaining supernatant to fill the buffer and centrifuge for another 20 minutes. The second collected supernatant is merged with the previous supernatant. Protein concentration is measured by Bradford analysis (Bio-Red). Mouse brain lysate exchange buffer was diluted to 3 mg / mL with sterile 1× PBS, aliquoted into 90 and 180 μL microcentrifuge tubes and stored at -80°C.
[0642] (B) Cell culture: Tau RD(LM)-eGFP HEK293 cells were cultured in two types of culture media. For cell maintenance, cells were cultured in DMEM / F-12 (Gibco) supplemented with 10% FBS (Gibco), 1% PS (Gibco) and 6 μg / mL puromycin (Gibco) and cultured at 1×10 6Cells were plated in 6-well plates (Greiner). Cells were subcultured twice a week. For tau binding assays, cells were cultured in DMEM / F-12 (binding medium) supplemented with 1.25% FBS, 1% PS, and 6 μg / mL puromycin and cultured at 1.5×10 4 Cells / well were plated in 96-well plates pre-coated with poly-D-lysine (BD Biosciences).
[0643] (C) Compound treatment: Frozen mouse brain lysate was thawed on ice and diluted to 1 μg / μL with 1×PBS. Diluted brain lysate or 1×PBS was added to each well of a 96-well plate containing cells cultured for 24 hours. After 24 hours of incubation, the medium was replaced with fresh binding medium. On the third day after tau inoculation, 10 mM compound stock solutions were serially diluted two-fold from 1000, 500, 250, 125, 62.5, 31.25, 15.63, 7.8 nM in fresh binding medium, and the DMSO (Sigma) concentration of all wells was maintained at 0.1%. The medium in the 96-well plate was then replaced with medium containing various concentrations of the compound. The plate was returned to the incubator for 2 hours, and the medium was replaced with binding medium containing 8% NucRed 647 (Thermo Fisher) to stain the nuclei for 30 minutes. Cells were fixed with 4% PFA (Electron Microscopy Sciences) for 20 minutes at room temperature and then replaced with 1× PBS for imaging.
[0644] (D) Image acquisition and analysis: All images were acquired by ImageXpress Micro Confocal (Molecular devices) using a 20× objective, and the excitation / emission settings were defined by DAPI, FITC20, and Cy5 channels for APN-0729, Tau-eGFP, and nuclei, respectively. All images were processed for tau binding analysis using a custom module of MetaXpress software (Molecular devices). The module is capable of measuring: (1) total cell number (= number of nuclei); (2) number of tau aggregates; (3) number of tau-positive cells; (4) average area of tau aggregates; (5) number of tau and compound double-positive aggregates; (6) number of tau and compound double-positive cells; (7) average compound intensity in tau aggregates; (8) area of tau and compound double-positive in tau aggregates.
[0645] Example 26: Tau degradation analysis
[0646] (A). Cell-based model of tau inclusion formation: Six-month-old rTg4510 mouse brain lysate was used as a tau seed source, prepared as described in Example 26 above. P301L-Tau-FL-GFP HEK293 cells represent HEK293 cells expressing full-length human tau T40 (2N4R), carrying the P301L mutation and a GFP tag (P301L-Tau-FL-GFP). 1×10 6 P301L-Tau-FL-GFP HEK293 cells were cultured in a 6-well plate in a medium containing DMEM / F-12 (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco), 1% penicillin-streptomycin (Gibco) and 0.5 mg / ml geneticin (Thermo Fisher Scientific) for 24 hours to reach 70% to 90% confluency, indicating that the cells are ready for transfection. 50 μg of 6-month-old rTg4510 mouse brain lysate was diluted in 400 μL serum-free medium and mixed with 16 μL of Lipofectamine 3000 reagent (Thermo Fisher Scientific) diluted in 400 μL serum-free medium. The solution mixture of rTg4510 brain lysate and Lipofectamine 3000 was incubated at room temperature for 25 minutes. The medium was removed, and then the solution mixture of rTg4510 lysate and Lipofectamine 3000 was added to the cells for transfection. The solution mixture was incubated at room temperature for five hours, after which the culture medium was replaced with 10% fetal bovine serum (FBS). After two days of incubation, Tau aggregates (Tau spots) were induced and images were acquired by the ImageXpress Micro Confocal high-capacity imaging system (Molecular Devices) as described in Example 52 above. Analysis was performed by two custom modules in MetaXpress software (Molecular Devices) for aggregated tau analysis. Outputs included the number of cells, the number of tau spots, the average intensity of tau spots, and the average size of tau spots.
[0647] (B) Compound treatment: 100 μL 3×10 4Cells containing Tau aggregates prepared as described above in step (A) were plated on 96-well plates coated with poly-D-lysine (BD Biosciences) and cultured for 24 hours. The compounds to be tested were dissolved in a culture medium containing 0.1% DMSO. Each of the test compounds at concentrations of 1, 0.2, and 0.04 μM was added to the cells containing Tau aggregates and incubated at 37°C for 24 hours. Thereafter, the culture medium was removed, the cells were washed with PBS solution and then lysed at 4°C for one hour using 30 μL of lysis buffer (PBS containing 0.3% Triton X-100 and 400 mM NaCl), and then the cell lysate was diluted with 170 μL of PBS containing 400 mM NaCl. The cell lysate was filtered through a 0.45 μM filter disk (Pall) and applied to Tau aggregation analysis.
[0648] (C). Control cell lysate: Control cell lysate was collected from non-seeded cells.
[0649] (D) ELISA-based Tau aggregation analysis: APNmAb005 ELISA kit for Tau aggregation analysis was designed and developed to detect abnormal tau aggregates in buffer solution or cell lysate by using anti-Tau APNmab005 as capture and detection antibodies. This antibody is a highly specific antibody that binds to human tau aggregates accumulated in mammalian cells. APNmAb005 is described in PCT patent application No. PCT / IB2020 / 057415 filed on August 5, 2020, which is incorporated herein by reference.
[0650] 100mM sodium carbonate buffer (pH 9.6) containing 0.15μg APNmAb005 was coated on a high-binding polystyrene 96-well microplate (Greiner Bio-One) overnight at 4°C. The microplate was washed with PBS and then treated with Intercept (PBS) blocking buffer (LI-COR) at room temperature for 2 hours. Thereafter, the microplate was washed with PBS, and then the cell lysate with compound treatment prepared as described in step (C) above was added to each well of the microplate and incubated at room temperature for 2 hours. The microplate was washed with PBS and then incubated with HRP-conjugated secondary antibody APNmAb005 for 3 hours at room temperature. HRP-conjugated secondary antibody APNmAb005 was prepared using an HRP-conjugated kit (Abcam, ab102890). The microplate was then washed with PBS and incubated with 100μL horseradish peroxidase (HRP) substrate at room temperature. After 20 minutes of incubation, the reaction was terminated by adding 100 μL of stop solution (Cell Signaling Technology). The optical density (OD) at 450 nm was measured using an EnVision microplate reader (PerkinElmer).
[0651] Figure 1 Degradation of Tau aggregates measured by APNmAb005 ELISA analysis is shown. After 1 μM compound 162842 treatment, the optical density (OD) 450 value decreased by 20% compared to vehicle, reflecting a reduction in Tau aggregates.
[0652] Some examples of compounds were evaluated in the Tau degradation assay. The results are summarized in Table 3.
[0653] Table 3.
[0654] Compound active 170350 + 160219 - 160313 - 160744 + 171177 - 161215 + 161409 + 160273 - 159985 - 162640 + 177031 - 162842 ++ 177038 - 174251 - 162903 + 160939 - 163123 + 160383 - 163365 +
[0655] Note: "++" indicates >20% reduction in tau aggregates after treatment with 1 μM compound
[0656] "+" indicates a 10% to 20% reduction in tau aggregates after treatment with 1 μM compound
[0657] “-” indicates <10% reduction in tau aggregates after treatment with 1 μM compound
[0658] Example 27: In vivo pharmacokinetic studies
[0659] To determine whether compounds of the invention are able to cross the blood-brain barrier (BBB), Example Compound 160313 (1 mg / kg, iv) was administered to mice in a pharmacokinetic study in plasma and brain tissue.
[0660] Animal husbandry: Mice were housed in an animal room environment with ventilation 15 times / hour, lighting 12 hours / day, temperature 20°C to 24°C and humidity 40% to 70%. The research room was sterilized and cleaned before the start of the study, and the operating area was cleaned after each dosing or sampling during the study. All animals had free access to food and water during the study. Animals had access to certified rodent diet (Certified Rodent Diet) and water at will. The nutritional composition and contaminant content of the feed and the impurities and contaminants of the water were monitored by a third-party organization. The health status of the animals was evaluated according to recognized animal husbandry procedures and was considered suitable for experimental purposes.
[0661] Sample collection and processing: Approximately 110 μL of whole blood was collected from all animals in tubes containing potassium ethylenediaminetetraacetate (K2EDTA) via facial or cardiac puncture under isoflurane anesthesia at 0.25, 0.5, 1, 2, 4, 8 and 24 hours after dosing. Brain samples were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 hours after dosing. Perfusion of pre-cooled saline was performed via cardiac puncture prior to brain collection. Blood samples were centrifuged at 2000 g at 4° C. for 5 minutes to obtain plasma samples by transferring the supernatant to a new tube. All plasma and brain samples were stored at approximately −70° C. until analysis.
[0662] Bioanalytical methods: The concentrations of compounds in plasma and brain samples were determined using a method based on liquid chromatography coupled to mass spectrometry (LC-MS / MS).
[0663] Results: The PK parameters are summarized in Table 4. Compound 160313 was able to penetrate the BBB in a short time. The brain / plasma ratio was about 0.31.
[0664] Table 4. In vivo pharmacokinetic profile of compound 160313
[0665] plasma brain <![CDATA[AUC last (hr×ng / mL)]]> 379 117 <![CDATA[T 1 / 2 (h)]]> 0.46 1.03 <![CDATA[C max (ng / mL)]]> - 111 <![CDATA[T max (h)]]> - 0.25
Claims
1. A compound of any one of formula I, formula II, formula IV and formula V, or a pharmaceutically acceptable salt thereof; in, L1 is -NR- or -O-, wherein R is hydrogen; L2 is substituted or unsubstituted C 1-50 A hydrocarbon chain selected from substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene, wherein the substituted 1-50 One or more atoms of the hydrocarbon chain are independently substituted by --O- or --NR a1 - permutation, where R a1 are independently hydrogen; Z is C or N; U is O, S or CH; K is CH; Q is CH; R'' is independently selected at each occurrence from the group consisting of: H, OH, NH2, C 1-6 Alkyl, C 1-6 Alkylamine, C 1-6 Alkoxy and halogen; k is 0, 1, 2 or 3; R′ is independently selected at each occurrence from the group consisting of: H, halogen, OH, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy; m is 0, 1, 2, 3 or 4; R″ is independently selected at each occurrence from the group consisting of: H, halogen, OH, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Alkylamine, C 3-6 Cycloalkylamino, C 3-6 Cycloalkyl and C 3-6 Heterocycloalkyl; n is 0, 1 or 2; J is CR 6 or N; x is CR 6 or N; Y is CR 6 or N; wherein one of J, x and Y is N; R 6 Independently selected from H, NH2, C 1-6 Alkyl and C 1-6 Alkoxy group, NH2, C 1-6 Alkyl or C 1-6 The alkoxy group may optionally be C 1-3 Alkyl, C 3-6 1 to 3 cycloalkyl and / or halo substituents; In Formula I, L3 is -NR- or -O-, wherein R is hydrogen; R 3′ H or C 1-6 Alkyl; Y1 is CH2 or V is N, wherein Z and U are not heteroatoms at the same time; In Formula II, R 2 ' is independently selected at each occurrence from the group consisting of: H, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Y1 is CH2 or V is N, wherein Z and U are not heteroatoms at the same time; In Formula IV, L3 is -NR- or -O-, wherein R is hydrogen; R 3′ is H or C1-6 alkyl; Y1 is CH2 or V is N; T is CH; wherein Z and U are not heteroatoms at the same time; In Formula V, R 2′ is independently selected at each occurrence from the group consisting of: H, OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Y1 is CH2 or V is N; T is CH; wherein Z and U are not heteroatoms at the same time.
2. The compound according to claim 1, wherein L2 is an optionally substituted C 1-45 Hydrocarbon chain.
3. The compound according to claim 1, wherein L2 is an optionally substituted C 1-30 A hydrocarbon chain, wherein one or more atoms of the hydrocarbon chain are independently connected by -O- or -NR a1 - permutation, where R a1 are independently hydrogen.
4. The compound according to claim 1, wherein L2 is a substituted or unsubstituted heteroalkylene group, wherein one or more chain atoms of the substituted group are independently -O- or -NR a1 - permutation, where R a1 are independently hydrogen.
5. The compound according to claim 4, wherein L2 comprises at least one example selected from the group consisting of: substituted or unsubstituted C 1-6 Alkylene and substituted or unsubstituted hetero C 1-6 Alkylene, wherein one or more chain atoms of the substituted group are independently -O- or -NR a1 - permutation, where R a1 are independently hydrogen.
6. The compound of claim 4, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted methylene, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, -(CH2)2-O(CH2)2-, -OCH2-, -O(CH2)2-, -O(CH2)3-, -O(CH2)4-, -O(CH2)5-, and -O(CH2)6-.
7. The compound according to claim 4, wherein L2 is an unsubstituted hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently substituted by -NR a1 - permutation, and R a1 Each instance of is independently hydrogen.
8. The compound according to claim 1, wherein L2 is Where g is 1, 2, 3, 4, 5 or 6.
9. The compound of claim 1, wherein L2 comprises the moiety -O- or -NH-.
10. The compound of claim 1, wherein L2 is selected from the group consisting of: wherein g is 1, 2, 3, 4, 5 or 6; f is 1, 2, 3, 4, 5 or 6, and h is 1, 2, 3, 4, 5 or 6.
11. The compound according to claim 1, wherein the compound of formula I has formula I-1; 12. The compound according to claim 1, wherein the compound of formula II has formula II-1; 13. The compound according to claim 1, wherein the compound of formula IV has the formula IV-1; 14. The compound according to claim 1, wherein the compound of formula V has the formula V-1; 15. The compound according to claim 11, wherein the compound of formula I-1 has formula 1, 5, 6, 8, 10 or 13; 16. The compound according to claim 15, wherein the compound has formula 1, and wherein R' is H, C 1-3 Haloalkyl or C 1-3 Alkoxy; and / or, R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 1-3 Alkylamino, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino and C 3-5 heterocycloalkyl; and / or, R″′ is H, OH or halogen; and / or, R 1′ is O or NH; and / or, A is O or NH; and / or, m2 is 2, 3, 4 or 6; and / or, R 3′ H or C 1-3 alkyl.
17. The compound according to claim 15, wherein the compound has Formula 5, and wherein R 3′ H or C 1-3 alkyl; and / or A is O or NH; and / or m4 is 1, 2 or 3; and / or m5 is 1; and / or m3 is 1, 2, 3, 4, 5 or 6; and / or R 1′ is O or NH; and / or, R″′ is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen; and / or, R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 alkoxy; and / or, m is 0, 1, 2 or 3; and / or, R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl.
18. The compound of claim 15, wherein the compound has formula 6, and wherein R 3′ H or C 1-3 alkyl; and / or A is O or NH; and / or m2 is 1, 2, 3, 4, 5, 6 or 7; and / or R 1′ is O or NH; and / or, R″′ is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen; and / or, R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 alkoxy; and / or, m is 0, 1, 2 or 3; and / or, R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 heterocycloalkyl; and / or n is 0 or 1.
19. The compound of claim 15, wherein the compound has formula 8, and wherein R 3′ H or C 1-3 alkyl; and / or, A is O or NH; and / or, m2 is 1, 2, 3 or 4; and / or, R 1′ is O or NH; and / or, R″′ is H, OH, C 1-3 Alkyl, C 1-3 alkoxy or halogen; and / or, k is 0 or 1; and / or, R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 alkoxy; and / or, m is 0, 1 or 2; and / or, R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamino, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 and / or n is 0, 1 or 2.
20. The compound of claim 15, wherein the compound has formula 10, and wherein R 3′ H or C 1-3 alkyl; and / or A is O or NH; and / or m5 is 1; and / or m4 is 1; and / or m3 is 1, 2, 3, 4 or 5; and / or R 1′ is O or NH, and / or, R″′ is H, OH, C 1-3 Alkyl, C 1-3 alkoxy or halogen; and / or, k is 0 or 1; and / or, R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 alkoxy; and / or, m is 0 or 1; and / or, R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 heterocycloalkyl; and / or n is 0 or 1.
21. The compound of claim 15, wherein the compound has formula 13, and wherein R 3′ H or C 1-3 alkyl; and / or, A is O or NH; and / or, m2 is 1, 2, 3 or 4; and / or, R 1′ is O or NH; and / or, R″′ is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen; and / or, R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 alkoxy; and / or, m is 0, 1, 2 or 3; and / or, R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamino, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl.
22. The compound according to claim 15, wherein the compound of formula 1 has formula 1-1; 23. The compound according to claim 15, wherein the compound of formula 5 has formula 5-1; 24. The compound according to claim 15, wherein the compound of formula 6 has formula 6-1; 25. The compound according to claim 22, wherein R 3′ H or C 1-3 Alkyl; A is O or NH; m2 is 1, 2, 3, 4, 5, 6 or 7; R 1′ is O or NH; R' is H, C 1-3 Haloalkyl or C 1-3 Alkoxy; R" is H, F, Cl, OH, NH2, C 1-3 Alkoxy, methylamino, dimethylamino, diethylamino or cyclopropylamino.
26. The compound according to claim 23, wherein R 3′ H or C 1-3 Alkyl; A is O or NH; m5 is 1; m4 is 1, 2, 3 or 4; m3 is 1, 2, 3, 4, 5 or 6; R 1′ is O or NH; R″′ is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen; R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; R" is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamino, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino and C 3-5 Heterocycloalkyl.
27. The compound according to claim 24, wherein R 3′ H or C 1-3 Alkyl; A is O or NH; m2 is 1, 2, 3, 4, 5, 6 or 7; R 1′ is O or NH; R″′ is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen; R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamino, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl.
28. The compound of claim 15, wherein the compound has Formula 1, 5, 6, 8, 10, or 13, and wherein K and Q are both CH.
29. The compound of claim 12, wherein the compound has Formula 3; 30. The compound according to claim 29, wherein R 2′ H, OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 alkylamino or NH2; and / or, m6 is 0, 1, 2 or 3; and / or, R 1′ is O or NH; and / or, R′ is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; and / or, R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3 Alkylamino; and / or, R″′ is H, OH, C 1-3 Alkyl, C 1-3 Alkoxy or halogen.
31. The compound of claim 29, wherein Z is C and U is O or S; or Z is N and U is CH; And / or, K and Q are both CH.
32. The compound of claim 29, wherein the compound has formula 3-1; 33. The compound according to claim 32, wherein R 2′ H, OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamine or NH2; m6 is 0, 1, 2 or 3; R 1′ is O or NH; R″ is H, halogen, OH, NH2, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3 Alkylamine.
34. The compound of claim 13, wherein the compound has formula 2, 7, 9, 11, 12 or 14; 35. The compound of claim 34, wherein the compound has Formula 2, and wherein R 3′ H or C 1-3 alkyl; and / or A is O or NH; and / or m2 is 2, 3, 4, 5 or 6; and / or R 1′ is O or NH; and / or, R″ is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamino, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl; and / or, R′ is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; and / or, m is 0, 1, 2 or 3; and / or, R"' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamino, C 1-3 Alkoxy or halogen.
36. The compound of claim 34, wherein the compound has formula 7, and wherein R 3′ H or C 1-3 alkyl; and / or A is O or NH; and / or m2 is 2, 3, 4, 5 or 6; and / or R 1′ is O or NH; and / or, R″ is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl; and / or, R′ is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 and / or m is 0, 1, 2 or 3.
37. The compound of claim 34, wherein the compound has formula 9, and wherein R 3′ H or C 1-3 alkyl; and / or A is O or NH; and / or m2 is 2, 3, 4, 5 or 6; and / or R 1′ is O or NH; and / or, R″ is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl; and / or, R′ is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; and / or, m is 0, 1, 2 or 3; and / or, R"' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen.
38. The compound of claim 34, wherein the compound has formula 11, and wherein R 3′ H or C 1-3 alkyl; and / or A is O or NH; and / or m2 is 2, 3, 4, 5 or 6; and / or R 1′ is O or NH; and / or, R″ is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl; and / or, R′ is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; and / or, m is 0, 1, 2 or 3; and / or, R"' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen.
39. The compound of claim 34, wherein the compound has formula 12, and wherein R 3′ H or C 1-3 Alkyl; A is O or NH; m3 is 1, 2, 3, 4, 5 or 6; m4 is 1, 2 or 3; m5 is 1; R 1′ is O or NH; R″ is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl; R' is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; m is 0, 1, 2 or 3; R″′ is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen.
40. The compound of claim 34, wherein the compound has formula 14, and wherein R 3′ H or C 1-3 alkyl; and / or A is O or NH; and / or m3 is 1, 2, 3, 4, 5 or 6; and / or m4 is 1, 2, 3 or 4; and / or m5 is 1; and / or R 1′ is O or NH; and / or, R″ is H, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Alkylamine, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 3-5 Heterocycloalkyl; and / or, R′ is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 alkoxy; m is 0, 1, 2 or 3; and / or, R"' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen.
41. The compound of claim 14, wherein the compound has formula 4; 42. The compound according to claim 41, wherein R 2′ H, OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 alkylamino or NH2; and / or, m6 is 0, 1, 2 or 3; and / or, R 1′ is O or NH; and / or, R′ is H, halogen, OH, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy; R" is H, halogen, OH, NH2, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Cycloalkylamino or C 1-3 Alkylamino; and / or, R"' is H, OH, NH2, C 1-3 Alkyl, C 1-3 Alkylamine, C 1-3 Alkoxy or halogen.
43. The compound of claim 41, wherein the compound has formula 4-1; 44. The compound of claim 1, wherein the compound is selected from the group consisting of:
45. A composition comprising a compound according to any one of claims 1 to 44 and a pharmaceutically acceptable excipient.
46. Use of a compound according to any one of claims 1 to 44 or a composition according to claim 45 for the manufacture of a medicament for the treatment of tauopathy.
